Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 5631. Отображено 100.
16-02-2012 дата публикации

Identification of Porcine Reproductive and Respiratory Syndrome Virus

Номер: US20120040335A1
Автор: Craig Welbon, Elizabeth M. Brown, Eric A. Nelson, Ying Fang
Принадлежит: South Dakota State University

An enzyme-linked immunosorbent assay (ELISA) is based on the non-structural protein 7 (nsp7) of porcine reproductive and respiratory syndrome virus (PRRSV) and provides for the simultaneous detection and differentiation of serum antibodies directed against Type 1 (European) and Type 2 (North American) PRRSV. The invention provides a serological assay for the detection and/or differentiation of serum antibodies directed against Type 1 and/or Type 2 PRRSV utilizing PRRSV nsp7 as an antigen, and provides a diagnostic method for the detection of PRRSV infection, epidemiological surveys, and outbreak investigations. The invention may be used either alone or as a follow-up assay to determine the true status of unexpected positive results that may occur using other assays, such as the IDEXX HERDCHEK PRRS ELISA.

Подробнее
Номер записи: 1
01-03-2012 дата публикации

Methods of diagnosing cervical cancer

Номер: US20120052484A1
Автор: Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer, Michael P. Belmares, Peter S. Lu
Принадлежит: Individual

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Подробнее
Номер записи: 2
08-03-2012 дата публикации

Differential immunoassay for prrs vaccine antibody

Номер: US20120058466A1
Автор: Kyoung-Jin Yoon, Wai-Hong Wu
Принадлежит: Iowa State University Research Foundation ISURF

The present invention relates to immunoassays for serologically differentiating animals naturally infected with PRRS virus from animals vaccinated against PRRS. The immunoassays provide detection of at least a portion of the N terminal region of the 2b portion of PRRSV. The immunoassay is preferably an enzyme-linked immunosorbent assay (ELISA).

Подробнее
Номер записи: 3
19-07-2012 дата публикации

Methods for screening and arraying microrganisms such as viruses using subtractive contact printing background

Номер: US20120184458A1
Автор: Daniel J. Solis, Emmanuel Delamarche, Sean R. Coyer
Принадлежит: International Business Machines Corp

Methods for screening and arranging microorganisms such as viruses in an array using subtractive contact printing are provided. In one embodiment, a method for forming an array of receptors for microorganisms comprises: patterning an array of structures on a first substrate to form a template on a surface of the first substrate; applying a receptor material to a face of a second substrate; and contacting the face of the second substrate with the template to remove a portion of the receptor material from the second substrate, thereby forming an array of receptors on the second substrate.

Подробнее
Номер записи: 4
07-02-2013 дата публикации

Cationic Steroid Antimicrobial Compositions and Methods of Use

Номер: US20130034500A1
Автор: Donald Y.M. Leung, Paul B. Savage
Принадлежит: Individual

The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

Подробнее
Номер записи: 5
27-06-2013 дата публикации

Method for promoting the synthesis of collagen and proteoglycan in chondrocytes

Номер: US20130164383A1
Автор: Koichi Masuda, Mitsuru Naiki
Принадлежит: Nippon Zoki Pharmaceutical Co Ltd, UNIVERSITY OF CALIFORNIA

The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.

Подробнее
Номер записи: 6
29-08-2013 дата публикации

Device and method for immunoassays

Номер: US20130224884A1
Автор: Bruno Colin, Cécile PARIS, Hélène BRIAND
Принадлежит: bioMerieux SA

A device for performing a test to determine the presence or the absence of at least one analyte in a liquid sample includes: a support and a matrix, fixed on the support. The matrix includes: a liquid sample application zone, a marking zone and at least one reaction zone. The one reaction zone includes: a test results display zone having at least a second immobilized binding partner which is able to bind to at least one analyte, and a monitoring zone downstream of the results display zone or parallel with the results display zone which allows monitoring of the correct functioning of the device and which includes at least one analogue of the at least one analyte which is able to bind to at least a first marked binding partner. The liquid sample application zone, marking zone and reaction zone are in fluid communication.

Подробнее
Номер записи: 7
05-09-2013 дата публикации

Papillomavirus pseudoviruses for detection and therapy of tumors

Номер: US20130230456A1
Автор: Douglas R. Lowy, Jeff Roberts, John T. Schiller
Принадлежит: National Institutes of Health NIH

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP)

Подробнее
Номер записи: 8
17-10-2013 дата публикации

Epitopes of herpes simplex virus

Номер: US20130273088A1
Автор: Anthony Lawrence Cunningham, Min Kim
Принадлежит: Individual

The present invention relates to diagnosis, prevention and treatment of Herpes simplex viruses and infection. In particular embodiments the present invention relates to methods and compositions for the prophylactic or therapeutic immunization against of infections of HSV. The present invention also relates to methods and compositions for diagnosis of the presence of and level of immunity to HSV. The invention also relates to peptide epitopes of HSV, in particular peptide epitopes of HSV2 glycoprotein D, to compositions thereof and to the use of such epitopes and compositions in methods for diagnosis, prevention and treatment of HSV.

Подробнее
Номер записи: 9
23-01-2014 дата публикации

Boone Cardiovirus

Номер: US20140024015A1
Автор: Judith D. Gohndrone, Lela Kay Riley, Matthew Howard Myles
Принадлежит: Idexx Laboratories Inc

The invention provides an isolated Boone cardiovirus, Boone cardiovirus polypeptides, polynucleotides and antibodies specific for Boone cardiovirus polypeptides. Also provided are methods for detection of Boone cardiovirus.

Подробнее
Номер записи: 10
27-03-2014 дата публикации

Method for generating, storing, transporting, eluting and detecting clinical relevant information in plasma using filter paper

Номер: US20140087363A1
Автор: Morten Ruhwald
Принадлежит: HVIDOVRE HOSPITAL

The present invention relates to a method that enables simpler, easier and more accurate determination cell mediated immune (CMI) responses using the biomarker IP-10 together with a simple and safe “dried blood spot” filter paper method of storing and shipping samples. The method is useful for the diagnosis and prognostication of diseases and conditions that can be diagnosed and prognosticated by measuring correlates of IP-10.

Подробнее
Номер записи: 11
07-01-2016 дата публикации

RECOMBINANT ANTIGENS OF PORCINE CIRCOVIRUS 2 (PCV-2) FOR VACCINE FORMULATIONS, DIAGNOSTIC KIT AND USE THEREOF

Номер: US20160000897A1
Автор: AMAZILES SILVA LEITE Roberta, ANDRADE TEIXEIRA Jackson de, BRESSAN Gustavo Costa, CRISPIM Josicelli Souza, DE ALMEIDA Márcia Rogéria, DE CRUZ SOUZA Amanda Martins, DE MORAIS MONTEIRO Antônio, FAUSTO Mariana Costa, FIALHO GONZAGA Natália, FIETTO Juliana Lopes Rangel, JAQUEL ZILCH Tiago, JUNIOR Abelardo Silva, KALKS Sthefany Patareli, LINO DE SOUZA Luiz Fernando, ONOFRE Thiago Souza, SALGADO Rafael Locatelli, VIDIGAL Pedro Marcus Pereira
Принадлежит:

The present invention relates to the preparation of the recombinant antigen of the viral capsid of 2 (PCV-2) and modifications thereof, upon expression in a prokaryotic system, purification in the monomer form, recovery of virus-like particles (VLPs) and their use in vaccine formulations, diagnostic kits and a system for quantifying in vaccine lots of the PCV-2 antigen by means of a capture ELISA assay. The antigens and vaccine formulations can be used in animal's immunization in programs for combatting PCV-2-associated diseases in conventional swine breeding systems, and represent alternatives to the commercially available vaccines. The ELISA kit can be used for testing the quality of commercial and/or experimental vaccines against PCV-2. 1porcine circovirus. Recombinant antigen of the 2 which is the SEQ ID NO: 02.2. Recombinant antigen according to claim 1 , which comprises 10 histidine residues positioned at amino terminal region of the capsid recombinant protein of the PCV-2.3. Recombinant antigen claim 1 , according to claim 1 , which comprises the product of the oligomerization of the SEQ ID NO: 02 as virus-like particles (VLPs) of the PCV-2.4. Vaccine Formulations claim 1 , which comprise the recovered antigen as defined in claim 1 , associated with pharmaceutically acceptable adjuvants.5. Capture Elisa type diagnostic kit which comprises the SEQ ID NO: 02 as defined in claim 1 , and anti-SEQ ID: 02 antibodies.6. Uses of the antigens as defined in claim 1 , which is applied in the production of diagnostic kits and the production of vaccine compounds.7. Use of the vaccine formulations defined in claim 4 , which is for the control of diseases related to the PCV-2.8. Use of the diagnostic kit as defined in claim 5 , which is for capsid protein quantification of the PCV-2 claim 5 , more specifically in quality control vaccine formulations.9. Recovery Process of the antigens and virus-like particles of claim 1 , which comprises the following steps:{'sub': 4', '2', ...

Подробнее
Номер записи: 12
04-01-2018 дата публикации

CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD)

Номер: US20180000927A1
Автор: ALBINA EMMANUEL, ARNAULD CLAIRE, BLANCHARD PHILIPPE, CARIOLET ROLAND, HUTET EVELYNE, JESTIN ANDRÉ, LE CANN PIERRE, MADEC FRANÇOIS, MAHE DOMINIQUE, TRUONG CATHERINE
Принадлежит: Zoetis Services LLC

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. 114.-. (canceled)15. A vaccine for protecting a pig against infection by a piglet weight loss disease circovirus comprising: an isolated ORF′2 polypeptide of porcine circovirus Type B (PCVB); and a recombinant expression vector.16. The vaccine of claim 15 , wherein the recombinant expression vector is a baculovirus expression vector.17. The vaccine of claim 15 , further comprising an adjuvant.18. The vaccine of claim 15 , further comprising a pharmaceutically or veterinarily acceptable carrier.19. The vaccine of claim 15 , wherein the ORF′2 polypeptide has at least 90% identity to the sequence of SEQ ID NO:26.20. The vaccine of claim 15 , wherein the ORF′2 polypeptide has at least 95% identity to the sequence of SEQ ID NO:26.21. The vaccine of claim 15 , wherein the ORF′2 polypeptide is encoded by a nucleic acid having at least 90% identity to the sequence of SEQ ID NO:25.22. A method for protecting a pig against infection by a piglet weight loss disease circovirus comprising: administering to the pig the vaccine of .23. The method of claim 22 , wherein the vaccine is administered to a pig 3 weeks of age or older.24. The method of claim 22 , wherein the vaccine is administered as a single dose.25. The method of claim 22 , wherein the vaccine is administered via a route selected from the group ...

Подробнее
Номер записи: 13
04-01-2018 дата публикации

Polypeptides And Antibodies For Treating HBV Infection And Related Diseases

Номер: US20180002382A1
Автор: CHEN Yixin, Luo Wenxin, Xia Ningshao, Yuan Quan, ZHANG JUN, Zhang Tianying
Принадлежит:

The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively. 126-. (canceled)27. A monoclonal antibody or an antigen binding fragment thereof , wherein the monoclonal antibody is derived from one of the following monoclonal antibodies or is selected from the following antibodies:1) the monoclonal antibody produced by the hybridoma cell line HBs-E6F6, wherein the hybridoma cell line HBs-E6F6 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO.C201270;2) the monoclonal antibody produced by the hybridoma cell line HBs-E7G11, wherein the hybridoma cell line HBs-E7G11 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO.C201271;3) the monoclonal antibody produced by the hybridoma cell line HBs-G12F5, wherein the hybridoma cell line HBs-G12F5 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO.C201272; and4) the monoclonal antibody produced by the monoclonal antibody produced by hybridoma cell line HBs-E13C5, wherein the hybridoma cell line HBs-E13C5 is deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO.C201273.28. The monoclonal antibody or antigen binding fragment of claim 27 , wherein the monoclonal antibody has one or more of the following ...

Подробнее
Номер записи: 14
04-01-2018 дата публикации

MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS

Номер: US20180002394A1
Автор: Debinski Waldemar, Gibo Denise, Pandya Hetal
Принадлежит:

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described. 114.-. (canceled)151. A nucleic acid that encodes a compound of claim comprising , in combination:an IL-13Rα2 binding ligand;at least one effector molecule;a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; anda subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule, andwherein said compound is a protein or peptide.16. A host cell that contains a nucleic acid of and expresses the encoded peptide.1719.-. (canceled)20. A method of detecting IL-13Rα2 expressing cells claim 15 , comprising administering a compound comprising claim 15 , in combination:an IL-13Rα2 binding ligand;at least one effector molecule;a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; anda subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule,to a cell or group of cells and detecting a detectable group coupled to said compound.21. A method of delivering at least one effector molecule to a subcellular compartment of a cell of interest claim 15 , comprising: an IL-13Rα2 ...

Подробнее
Номер записи: 15
04-01-2018 дата публикации

HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF

Номер: US20180002675A1
Автор: Comer James A., Ksiazek Thomas G., Nichol Stuart T., Rollin Pierre E., Towner Jonathan S.
Принадлежит: The United States of America, as represented by the Secretary, Department of Health and Human Serv

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection. 1. A vector , comprising a nucleic acid molecule encoding at least 70 contiguous residues of the amino acid sequence of SEQ ID NO: 9 (GP)2. The vector of claim 1 , wherein the nucleic acid molecule encodes at least 80 contiguous residues of the amino acid sequence of SEQ ID NO: 9.3. The vector of claim 1 , wherein the nucleic acid molecule encodes of at least 100 contiguous residues of the amino acid sequence of SEQ ID NO: 9.4. The vector of claim 1 , wherein the nucleic acid molecule encodes at least 200 contiguous residues of the amino acid sequence of SEQ ID NO: 9.5. The vector of claim 1 , wherein the nucleic acid molecule encodes at least 300 contiguous residues of the amino acid sequence of SEQ ID NO: 9.6. The vector of claim 1 , wherein the nucleic acid molecule encodes at least 400 contiguous residues of the amino acid sequence of SEQ ID NO: 9.7. The vector of claim 1 , wherein the nucleic acid molecule encodes at least 500 contiguous residues of the amino acid sequence of SEQ ID NO: 9.8. The vector of claim 1 , wherein the nucleic acid molecule encodes at least 600 contiguous residues of the amino acid sequence of SEQ ID NO: 9.9. The vector of claim 1 , wherein the nucleic acid molecule encodes the amino acid sequence of SEQ ID NO: 9.10. The vector of claim 1 , wherein the vector is a recombinant vesicular stomatitis virus vector.11. A method of inducing an immune response in a subject claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering an effective amount of the vector of to the subject to induce the immune response.'}12. The method of claim 11 , wherein the immune response inhibits Ebola virus ...

Подробнее
Номер записи: 16
01-01-2015 дата публикации

PRION DISEASE-SPECIFIC EPITOPES AND METHODS OF USE THEREOF

Номер: US20150004185A1
Автор: Cashman Neil, Marciniuk Kristen, Napper Scott, POTTER Andrew, Taschuk Ryan
Принадлежит: UNIVERSITY OF SASKATCHEWAN

Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease. 1. An isolated immunogenic peptide selected from a peptide comprising (a) the sequence GYMLGSAMSRP (SEQ ID NO:17); (b) the sequence VDQYSNQNNF (SEQ ID NO:19); or (c) a sequence corresponding to (a) or (b) from another species.2. A fusion peptide comprising two or more repeats of the immunogenic peptide of in a linear or an inverted orientation.3. The immunogenic peptide of claim 2 , wherein said peptide comprises the amino acid sequence of SEQ ID NO:38.4. The immunogenic peptide of claim 2 , wherein said peptide comprises the amino acid sequence of SEQ ID NO:43.5. The immunogenic peptide of claim 2 , wherein said peptide comprises the amino acid sequence of SEQ ID NO:48.6. An immunogenic peptide comprising the amino acid sequence of SEQ ID NO:37.7. The immunogenic peptide of claim 1 , linked to a carrier molecule.8. The immunogenic peptide of claim 7 , wherein the carrier molecule is an RTX toxin.9. The immunogenic peptide of claim 8 , wherein the carrier molecule is a leukotoxin polypeptide.10. The immunogenic peptide of claim 9 , wherein the leukotoxin polypeptide is LKT 352.11. The immunogenic peptide of claim 7 , wherein the carrier molecule is a lyssavirus glycoprotein G or a portion thereof comprising a deletion of all or part of the C-terminal transmembrane and cytoplasmic domains.12. The immunogenic peptide of claim 11 , wherein the lyssavirus glycoprotein G comprises the sequence of amino acids of SEQ ID NO:49.13. A composition comprising one or more of the immunogenic peptides of and a pharmaceutically acceptable vehicle.14. The composition of comprising an immunogenic peptide with the amino acid sequence of SEQ ID NO:38 claim 13 , and an immunogenic peptide with the amino acid sequence of SEQ ID NO:43 or SEQ ID NO:48.15. The composition of claim 14 , further comprising an ...

Подробнее
Номер записи: 17
01-01-2015 дата публикации

Semi-quantitative lateral flow assays

Номер: US20150004594A1
Автор: Sibbett Scott S.
Принадлежит:

The present invention provides a semi-quantitative lateral flow assay device and method for generating semi-quantitative data from a lateral flow assay. The device comprises a thin, porous hydrophilic substrate wherein the substrate includes a star-shaped or other geometry taken in plan view having a liquid sample-receiving central region and multiple arms that extend or radiate out from the central region. Each arm includes a reaction zone formed by the presence of an analyte-capturing agent wherein the reaction zone of each arm is located at a different distance from the central region such that the analyte in the sample is captured accumulates in different quantities at at least some of the reaction zones of the arms in a manner that can be analyzed to yield semi-quantitative data from lateral flow assays. The reaction zones on the arms can be analyzed visually and/or by software analysis of a digital image based on color saturation, grayscale, or other characteristics of the reactions zones due to the presence of different amounts of analyte to produce semi-quantitative data of the total loading of a virus or other agent of interest of a patient's blood. 1. A device for performing semi-quantitative lateral flow assay , comprising:porous hydrophilic substrate wherein the substrate includes, in plan view, a liquid sample-receiving central region and multiple arms that extend out from the central region, wherein each arm includes a localized reaction zone, and wherein the reaction zone of each arm is located at a different distance relative to the central region such that the analyte in the sample resides in different quantities at at least some of the reaction zones of the arms in a manner that can be analyzed to yield semi-quantitative data from the lateral flow assay.2. The device of wherein the substrate has claim 1 , in plan view claim 1 , a star-shaped geometry with a circular central region and the multiple arms radiating out from the central region.3. The ...

Подробнее
Номер записи: 18
04-01-2018 дата публикации

Method for producing antibody reagent

Номер: US20180003707A1
Автор: Aya MORIMOTO, Seiichi Hashida, Takahiro Yamagaito, Toshihiro Watanabe
Принадлежит: Sysmex Corp

Disclosed is a method for producing an antibody reagent for detecting a test substance in a sample by an immune complex transfer method. The method comprises the steps of: bringing an antibody solution comprising a labeled antibody capable of binding to the test substance into contact with a solid phase used in the immune complex transfer method; and separating the solid phase and the antibody solution to prepare the antibody reagent from the antibody solution.

Подробнее
Номер записи: 19
13-01-2022 дата публикации

IN VITRO ASSAY FOR DETECTING ENHANCERS AND INHIBITORS OF ADENO ASSOCIATED VIRUS (AAV) VECTOR TRANSDUCTION AND/OR DETECTING OR QUANTITATING ANTI-AAV BINDING ANTIBODIES

Номер: US20220011308A1
Автор: ANGUELA Xavier, KURANDA Klaudia, Mingozzi Federico
Принадлежит: SPARK THERAPEUTICS, INC.

Disclosed herein are methods for analyzing for or detecting the presence of non-antibody inhibitors and/or enhancers of adeno-associated virus (AAV) vector cell transduction in a biological sample from a subject. Also disclosed herein are methods for analyzing for, or detecting the presence of, AAV binding antibodies that inhibit, reduce or decrease AAV vector cell transduction in a biological sample from a subject. The methods rely, in part, on the use of empty capsid AAV particles to absorb AAV binding antibodies, to detect enhancers or inhibitors of AAV vector cell transduction, when present, in a biological sample analyzed for AAV neutralizing antibodies (NAbs). 1. A method for analyzing for or detecting the presence of enhancers of adeno-associated virus (AAV) vector cell transduction in a biological sample from a subject , comprising: (i) said vector comprises a reporter transgene,', '(ii) said reporter transgene comprises a single-stranded or a self-complementary genome,', '(iii) said reporter transgene is operably linked to one or more expression regulatory element; and', '(iv) said reporter transgene is flanked by one or more flanking element;, '(a) providing infectious recombinant AAV particles comprising a recombinant AAV vector, wherein'}(b) providing cells that can be infected with said infectious recombinant AAV particles;(c) contacting said cells of (b) with said infectious recombinant AAV particles of (a) under conditions in which said cells of (b) are transduced by said infectious recombinant AAV particles of (a) and said reporter transgene is expressed by said cells of (b);(d) measuring expression of said reporter transgene and assigning a value denoted MAX that reflects the amount of reporter transgene expression of (c);(e) providing infectious recombinant AAV particles of (a);(f) providing a biological sample from a subject;(g) providing cells that can be infected with said infectious recombinant AAV particles;(h) mixing said biological sample of ...

Подробнее
Номер записи: 20
13-01-2022 дата публикации

METHOD OF ASSESSING RISK OF PML

Номер: US20220011310A1
Автор: Bloomgren Gary Lewis, Bozic Carmen, Lee Sophia, Plavina Tatiana, Subramanyam Meena
Принадлежит:

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML). 185.-. (canceled)86. A method of treating a Multiple Sclerosis (MS) patient , the method comprising acquiring the result of an assay for detecting JC Virus (JCV) antibodies in a biological sample from the patient , and responsive to a determination that the sample is negative for anti-JCV antibodies , administering an anti-VLA-4 therapy , wherein the assay comprises:a) forming a first reaction mixture comprising a first aliquot of said sample and a substrate on which is disposed highly purified viral-like particles (HPVLP);b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLP by detecting a labeled detection reagent bound to anti-JCV antibody bound to said substrate, evaluating a cut-off calibrator having a score of about 1, a positive control having a score of about 1.3, and a negative control having a score of about 0.1, and assigning to the sample a value indicative of the level of anti-JCV antibody;c) responsive to a level of anti-JCV antibody corresponding to a nOD value between 0.2 and 0.4 in step b), forming a second reaction mixture containing a second aliquot of said sample and solution-phase HPVLP, and detecting the level of unbound antibody in said second reaction mixture, by detecting anti-JCV antibody capable of binding with a substrate on which is disposed HPVLP;d) forming a third reaction mixture containing a third aliquot under conditions where anti-JCV antibodies in the sample are not bound by HPVLP or other antigen, and detecting the level of unbound anti-JCV antibody in the third reaction mixture by detecting anti-JCV antibody capable of binding with a substrate on which is disposed HPVLP; ande) determining the level to which the presence of HPVLP in the second reaction mixture inhibits the level of unbound anti-JCV antibody in said second reaction as compared with the level of ...

Подробнее
Номер записи: 21
27-01-2022 дата публикации

Methods of Selecting T Cell Line and Donor Thereof for Adoptive Cellular Therapy

Номер: US20220023417A1
Автор: "OReilly Richard J.", Doubrovina Ekaterina, Hasan Aisha N., Koehne Guenther, Prockop Susan E.
Принадлежит: Memorial Sloan Kettering Cancer Center

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. 1. A method of selecting an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer , comprising:selecting a T cell line allogeneic to the patient that recognizes at least one epitope of an antigen of the pathogen or the cancer, using a representation that (i) identifies a plurality of HLA alleles and optionally HLA allele combinations, and (ii) discloses indications of relative activities of T cell lines, each recognizing at least one epitope of an antigen of the pathogen or cancer, and restricted to different ones of the HLA alleles or HLA allele combinations in the plurality; wherein in the representation each identified HLA allele or HLA allele combination is associated with the respective indication of relative activity of the T cell line restricted to the HLA allele or HLA allele combination, the relative activities being relative measures of known activity against the pathogen or against the cancer exhibited by the T cell lines; wherein(A) the T cell line selected has in common with the patient or diseased cells in the patient the HLA allele or HLA allele combination identified by the representation to which the recognition of the T cell line is restricted; and(B) the HLA allele or HLA allele combination, to which the T cell line selected is restricted, is associated in the representation with an indication of the highest relative activity among the HLA alleles and HLA allele combinations in the representation that are known to be in common with the patient or the diseased cells in the patient and are not otherwise disqualified.2. The method of ...

Подробнее
Номер записи: 22
08-01-2015 дата публикации

METHOD FOR DETECTING POLYOMAVIRUS REACTIVATION

Номер: US20150010901A1
Автор: Khalili Kamel, Sariyer Ilker K.
Принадлежит: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease. 1. A method for detection of polyomavirus reactivation in a patient having or suspected of having a latent polyomavirus infection , the method comprising determining the presence or absence of a polyomavirus agnoprotein and/or the presence or absence of agnoprotein antibodies in the biological sample , wherein the biological sample is a body fluid , and wherein the presence of the polyomavirus agnoprotein or agnoprotein antibodies is indicative of reactivation of the polyomavirus in the patient.2. The method of claim 1 , wherein the polyomavirus is a mammalian polyomavirus claim 1 , a primate polyomavirus or a human polyomavirus.3. The method of claim 2 , wherein the polyomavirus is a human polyomavirus.4. The method of claim 3 , wherein the human polyomavirus is JC virus or BK virus.5. The method of claim 1 , wherein the biological sample is a body fluid selected from the group consisting of blood claim 1 , blood serum claim 1 , blood plasma claim 1 , urine claim 1 , and cerebrospinal fluid.6. The method of claim 1 , further comprising: 'comparing the level of the polyomavirus agnoprotein or agnoprotein antibodies in the biological sample to the level of polyomavirus agnoprotein or agnoprotein antibodies in a control sample,', 'measuring the level of the polyomavirus agnoprotein in the biological sample, and'}wherein an elevated level of the polyomavirus agnoprotein or agnoprotein antibodies in the biological sample relative to the level of polyomavirus agnoprotein or agnoprotein antibodies in the control sample is indicative of reactivation of the polyomavirus in the patient.7. The method of claim 6 , wherein the control sample is a positive control sample claim 6 , andwherein a level of the ...

Подробнее
Номер записи: 23
14-01-2016 дата публикации

MONOCLONAL ANTIBODIES THAT NEUTRALIZE A NOROVIRUS

Номер: US20160009788A1
Автор: Bok Karin, CHEN Zhaochun, Green Lisbeth Kim, PURCELL Robert H., Sosnovtsev Stanislav
Принадлежит: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Norwalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections. 2. (canceled)3. The isolated monoclonal antibody of claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence set forth as one of SEQ ID NO: 8 claim 1 , SEQ ID NO: 24 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 56 claim 1 , SEQ ID NO: 72 claim 1 , SEQ ID NO: 88 claim 1 , SEQ ID NO: 104 claim 1 , SEQ ID NO: 120 claim 1 , or SEQ ID NO: 136.4. The isolated monoclonal antibody of claim 1 , wherein the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 16 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 48 claim 1 , SEQ ID NO: 64 claim 1 , SEQ ID NO: 80 claim 1 , SEQ ID NO: 96 claim 1 , SEQ ID NO: 112 claim 1 , SEQ ID NO: 128 or SEQ NO: 144.5. (canceled)6. The isolated monoclonal antibody of claim 1 , wherein:(a) the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 8 and the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 16;(b) the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 24 and the light chain variable domain comprises ...

Подробнее
Номер записи: 24
12-01-2017 дата публикации

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES

Номер: US20170010264A1
Автор: ANYANWU Sam, Newman Gale W.
Принадлежит:

A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject. 1. A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject caused by a hepatitis virus , comprising:(a) preparation of an exosome(s) from a bodily fluid sample from a subject;(b) contacting said exosome preparation with one or more hepatitis virus-associated biomarker binding agent(s) selective for a hepatitis virus and/or one or more detection reagent(s) suitable for detecting one or more hepatitis virus-associated biomarker(s); and(c) determining whether the exosome preparation comprises at least one hepatitis virus biomarker,wherein a determination of the presence of the at least one hepatitis virus-associated biomarker in step (c) is indicative of a hepatitis virus infection or hepatitis disease condition in the subject and wherein a determination of the absence of the at least one hepatitis virus-associated biomarker in step (c) is indicative of the absence of hepatitis virus infection or a hepatitis disease condition in the subject.2. The method of claim 1 , wherein the bodily fluid is urine.3. The method of claim 1 , wherein the exosome preparation comprises whole exosomes.4. The method of claim 1 , wherein the exosome preparation comprises an exosome lysate.5. ...

Подробнее
Номер записи: 25
10-01-2019 дата публикации

POTENCY TEST FOR VACCINE FORMULATIONS

Номер: US20190011420A1
Автор: ALLEN MICHELLE, BRUDERER URS PETER, GARRETT MARK, THIJSSEN MARTINUS ANTONIUS JOHANNES
Принадлежит: Intervet Inc.

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen. 1. A method for the determination of an antigen content of a first antigen in a mixture of at least a composition comprising the first antigen and a composition comprising (i) a second antigen and (ii) antibodies that are capable of binding with the first antigen , the method comprising the steps of:a) dissociating antigen-antibody complexes in the mixture, formed between the first antigen and the antibodies; andb) determining the antigen content of the first antigen by means of an immunoassay.2Mycoplasma hyopneumoniae. The method of claim 1 , wherein the first antigen is a porcine circovirus type 2 (PCV-2) antigen and the second antigen is a antigen.3. The method of claim 1 , wherein the immunoassay is an ELISA (enzyme linked immunosorbant assay).4. The method of claim 1 , wherein the mixture is a ready-to-use vaccine formulation.5. The method of claim 1 , wherein the mixture is incubated with an acid solution to dissociate the antigen-antibody complexes.6. The method of claim 5 , wherein the acid solution is a citric acid solution.7. The method of claim 5 , wherein the mixture is incubated with the acid solution for at least 8 hours.8. The method of claim 5 , wherein the mixture is incubated at a ratio (v/v) between the acid solution and the mixture of at least 25 claim 5 , preferably 25-75 claim 5 , more preferably 25-50.9. The method of claim 5 , wherein the acid solution has a pH of 1.0-3.0.10Mycoplasma hyopneumoniaeM. hyo. A method for the determination of an antigen content of a porcine circovirus type 2 (PCV-2) antigen in a mixture of at least a composition comprising the PCV- ...

Подробнее
Номер записи: 26
14-01-2021 дата публикации

BOVINE HERPESVIRUS DETECTION AND TREATMENT

Номер: US20210011017A1
Автор: Chowdhury Shafiqul Islam
Принадлежит: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine. 118.-. (canceled)19. A method comprising:(a) contacting a test sample from an animal with at least one polypeptide or peptide to form an assay mixture, where the at least one polypeptide or peptide is selected from the group consisting of a polypeptide or peptide comprising an N-terminal six histidine tag and a sequence segment with at least 95% sequence identity to a sequence of SEQ ID NO:1, and a polypeptide or peptide comprising the sequence segment of SEQ ID NO:4; and(b) detecting or measuring whether a complex between the at least one polypeptide or peptide and antibodies is present in the assay mixture.20. The method of claim 19 , further comprising determining whether said animal is infected with a Bovine herpesvirus type 1 (BoHV-1) claim 19 , vaccinated with a recombinant BoHV-1 triple mutant virus (BoHV-1 tmv) claim 19 , or uninfected with a Bovine herpesvirus type 1 (BoHV-1) claim 19 , at least in part from said detecting or measuring whether a complex between the at least one polypeptide or peptide and antibodies is present in the assay mixture.21. The method of claim 19 , wherein the at least one polypeptide or peptide is immobilized on a solid surface.22. The method of claim 21 , where the solid surface comprises a chip claim 21 , strip claim 21 , paper claim 21 , microtiter plate claim 21 , bead claim 21 , test tube claim 21 , slide claim 21 , gel claim 21 , or filter.23. The method of claim 21 , where the solid surface comprises glass claim 21 , plastic claim 21 , cellulose claim 21 , ethylcellulose claim 21 , methylcellulose claim 21 , paper claim 21 , nitrocellulose claim 21 , hydroxypropylcellulose claim 21 , hydroxypropyl methylcellulose claim 21 , polystyrene claim 21 , polyethylene claim 21 , lipid polydiacetylene (PDA) claim 21 , ...

Подробнее
Номер записи: 27
14-01-2021 дата публикации

METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES

Номер: US20210011025A1
Автор: Daugherty Patrick, Kamath Kathryn, REIFERT Jack
Принадлежит:

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The of an antibody specificity in method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition. 1. A method of characterizing a phenotype in a biological sample comprising: i) providing a biological sample comprising a plurality of antibodies;', 'ii) contacting the biological sample with a plurality of peptides; and', 'iii) identifying members of the plurality of peptides that form a complex with members of the plurality of antibodies;', 'iv) determining at least one peptide motif from the members of the plurality of peptides identified in iii), wherein determining the at least one peptide motif comprisesaligning the sequences of the members of the plurality of peptides identified in iii); and wherein the aligning comprises using a computational alignment algorithm;, 'a) identifying at least one peptide motif in the biological sample comprisingb) comparing the presence or level of the at least one peptide motif identified in step a) to a reference value; andc) identifying at least one peptide motif with a presence or level that differs from the reference based on the comparison in b),thereby identifying the at least one peptide motif indicative of the phenotype.2. The method of claim 1 , wherein the biological sample is any one or more of peripheral blood claim 1 , lymphatic fluid claim 1 , cerebral spinal fluid claim 1 , sweat claim 1 , urine claim 1 , saliva claim 1 , mucus claim 1 , or a derivative of any thereof.3. The method of claim 1 , wherein the reference value comprises a presence or level of the same peptide motif in a control sample.4. The method of claim 3 , wherein the control sample has a different phenotype than the biological sample.5. The method of claim 1 , wherein the phenotype comprises a disease ...

Подробнее
Номер записи: 28
03-02-2022 дата публикации

TEMPERATURE CONTROLLED VALVES FOR PAPER-BASED MICROFLUIDIC SYSTEMS

Номер: US20220032286A1
Автор: Chiu Megan Zaiyi, Linnes Jacqueline C., SHEN Rui
Принадлежит: PURDUE RESEARCH FOUNDATION

The present invention relates to a low-cost, thermally reversible valve for paper-fluidic diagnostic devices. In particular, this invention demonstrates a tunable valve mechanism fabricated by wax-ink printing and localized heating via thin-film resistors to sequentially release liquids through a cellulose or nitrocellulose membrane. The wax-ink valve can obstruct fluid flow for a sustained time and are thermally actuated to release a controlled amount of liquid past the valve. This integrated paper-fluidic diagnostic assay device requires minimal user involvement, can be easily manufactured and tuned to meet various fluid delivery timing and incubation needs. 1. A method for testing a sample for the presence or absence of a nucleic acid of said sample comprising the steps of: a first thermally reversible barrier, wherein the first thermally reversible barrier defines an assay area, and a plurality of heating and temperature control components comprising a conductive ink printed resistor operatively positioned proximate said first thermally reversible barrier, wherein the first thermally reversible barrier includes an associated inlet and an associated outlet across a membrane and selectively operates according to four states: 1) an un-actuated state, where the first thermally reversible barrier is placed adjacent the membrane whereby fluid is free to travel across the membrane; 2) an actuated state when temperature of the first thermally reversible barrier is raised to a first predetermined threshold, where the first thermally reversible barrier melts and permeates into the membrane whereby fluid is stopped from travelling across the membrane, after which the temperature is allowed to be at or below the first predetermined threshold; 3) a closed state when temperature of the first thermally reversible barrier is below a second predetermined threshold, where the first thermally reversible barrier remains permeated in the membrane thereby fluid is stopped from ...

Подробнее
Номер записи: 29
18-01-2018 дата публикации

ANTIBODIES SPECIFIC TO GLYCOPROTEIN (GP) OF EBOLAVIRUS AND USES FOR THE TREATMENT AND DIAGNOSIS OF EBOLA VIRUS INFECTION

Номер: US20180016322A1
Автор: REYNARD Olivier, VOLCHKOV Viktor
Принадлежит:

The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease. 1. An isolated neutralizing antibody characterized in that it binds to a conformational epitope of Ebolavirus glycoprotein GP of SEQ ID NO:18 , wherein said antibody has an SN50 of 10 μg/ml or below as measured in a seroneutralization assay with Zaire Ebolavirus.2. The isolated neutralizing antibody of claim 1 , wherein said isolated neutralizing antibody has at least one of more the following properties:(i) it binds to a thermolysin digested form of Ebolavirus glycoprotein GP;(ii) it further neutralizes Sudan, Reston and Taï Forrest Ebolavirus species;(iii) it does not bind to a mutant EBOV GP having a G528E amino acid mutation; and/or,(iv) it neutralizes a mutant strain of Ebolavirus having GP with escape mutation Q508A.3. The isolated neutralizing antibody of claim 1 , wherein said isolated neutralizing antibody prevents translocation of genetic material of Ebolavirus in the cytosol.4. The isolated neutralizing antibody of claim 1 , characterized in that it is selected from the group consisting of:(i) an antibody comprising a heavy chain having a VH-CDR1 as set forth in SEQ ID NO:6, VH-CDR2 as set forth in SEQ ID NO:7 and VH-CDR3 as set forth in SEQ ID NO: 8 and a light chain having a VL-CDR1 as set forth in SEQ ID NO:14, VL-CDR2 as set forth in SEQ ID NO:15 and VL-CDR3 as set forth in SEQ ID NO:16;(ii) a murine antibody which comprises a VL domain of SEQ ID NO:5 and a VH domain of SEQ ID NO:13;(iii) a chimeric or humanized antibody obtained from the murine antibody of ii); and,(iv) antigen-binding fragments of an antibody of i) to iii).5. The isolated neutralizing antibody of claim 4 , wherein said antigen-binding fragments are selected from Fv claim 4 , Fab claim 4 , F(ab′)2 claim 4 , Fab′ claim 4 , dsFv claim 4 , scFv claim 4 , sc(Fv)2 claim 4 , diabodies claim 4 , ...

Подробнее
Номер записи: 30
21-01-2021 дата публикации

Method for preparing foot-and-mouth disease virus-like particles, and test strip for detecting foot-and-mouth disease

Номер: US20210016272A1
Автор: Hong Yin, Huichen GUO, Jianxun LUO, Jiaxi RU, Ping Du, Shiqi SUN, Xiangtao Liu, Xiaoying ZHI, Yanquan WEI, Yanyan CHANG, Yun Zhang
Принадлежит: Lanzhou Veterinary Research Institute of CAAS

A test strip for detecting a serotype O foot-and-mouth disease, the test strip including: a bottom board; a detection layer being disposed on the bottom board and including a detection line and a control line; an absorbent layer being disposed at one end of the detection layer close to the control line; a gold colloidal conjugate pad being disposed at the other side of the detection layer close to the detection line; and a sample pad is disposed on a top of the gold colloidal conjugate pad. The gold colloidal conjugate pad is coated with colloidal gold particles that are conjugated with a Staphylococcus protein A (SPA) marker. The detection line is coated or impregnated with serotype O FMDV-like particles, and the control line is coated or impregnated with rabbit IgG.

Подробнее
Номер записи: 31
17-01-2019 дата публикации

METHOD FOR DIAGNOSING, TREATING, OR PREVENTING MOOD DISORDERS

Номер: US20190018022A1
Автор: KOBAYASHI Nobuyuki, KONDO Kazuhiro, Oka Naomi
Принадлежит:

An embodiment of the present invention provides a novel method for diagnosing, treating, or preventing a mood disorder. The method includes the step of measuring, by using a fusion protein, a level of the anti-fusion protein antibody in a biological sample. 1. A fusion protein comprising a SITH-1 protein and a CAML protein.2. The fusion protein as set forth in claim 1 , wherein:an N-terminal side of the CAML protein is bound to a C-terminal side of the SITH-1 protein.3. The fusion protein as set forth in claim 1 , wherein:a C-terminal side of the CAML protein is bound to an N-terminal side of the SITH-1 protein.4. A support to which a fusion protein recited in is immobilized.5. (canceled)6. A measurement method comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'measuring, by using a fusion protein recited in , a level of the anti-fusion protein antibody in a biological sample isolated from a subject.'}7. The measurement method as set forth in claim 6 , further comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting a labeled anti-CAML antibody with a cell in which the fusion protein recited in is expressed.'}8. A diagnosis method for a mood disorder in a human subject claim 6 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'measuring an antibody level in a biological sample isolated from the human subject, the antibody level being an antibody level of an antibody (anti-fusion protein antibody) recognizing a fusion protein recited in .'}9. The diagnosis method as set forth in claim 8 , further comprising the step of:measuring a level of an antibody (anti-fusion protein antibody) recognizing the fusion protein,the fusion protein being a fusion protein in which an N-terminal side of the CAML protein is bound to a C-terminal side of the SITH-1 protein.10. The diagnosis method as set forth in claim 9 , using the fusion protein.11. The diagnosis method as set forth in claim 8 , further comprising ...

Подробнее
Номер записи: 32
16-01-2020 дата публикации

METHODS FOR DETERMINING POTENCY OF ADENO-ASSOCIATED VIRUS PREPARATIONS

Номер: US20200018752A1
Автор: BENDIK Marian, BOEHM Ernst, Fiedler Christian, Graninger Michael, NECINA Roman
Принадлежит:

Provided herein are methods of measuring the qualitative and/or quantity attributes of gene therapy vector preparations. In certain embodiments, the gene therapy vector preparations are AAV preparations (e.g., AAV8). In certain embodiments the methods comprise determining the potency or dose of the AAV preparation using ELISA or ELISA in combination with CryoTEM. 1. A method of quantifying the dose of an AAV preparation , comprising quantifying a total number of AAV capsids in the AAV preparation via an AAV-specific ELISA assay.2. A method of quantifying the dose of an AAV preparation , comprising quantifying a total number of AAV capsids in the AAV preparation via an AAV-specific ELISA assay and evaluating a percentage or ratio of full versus empty (full:empty) AAV capsids in the AAV preparation via cryogenic transmission electron microscopy (CryoTEM).3. A method of measuring the concentration of full AAV capsids in an AAV preparation , comprising quantifying a total number of AAV capsids in the AAV preparation via an AAV-specific ELISA assay and evaluating a percentage of full versus empty AAV capsids in the AAV preparation via cryogenic transmission electron microscopy (CryoTEM).4. The method of any one of the proceeding claims , wherein the ELISA assay is a sandwich ELISA , direct ELISA , indirect ELISA , or competitive ELISA assay specific for an AAV antigen.5. The method of any one of the proceeding claims , wherein the ELISA assay is a sandwich ELISA assay specific for an AAV antigen.6. The method of claim 1 , further comprising evaluating a percentage or ratio of full versus empty (full:empty) AAV capsids in the AAV preparation.7. The method of any one of the proceeding claims claim 1 , wherein the evaluating step is conducted before or after the ELISA assay.8. The method of or claim 1 , wherein the evaluating step comprises determining the percentage or ratio of full:empty AAV capsids by cryogenic transmission electron microscopy (CryoTEM) claim 1 , ...

Подробнее
Номер записи: 33
28-01-2016 дата публикации

Systems And Methods For Early Detection Of Cervical Cancer By Multiplex Protein Biomarkers

Номер: US20160025729A1
Автор: Gombrich Peter Paul, Kim Nam Woo
Принадлежит:

Method for diagnosis and prognosis of premalignant and malignant cervical disease by using multiple neoplastic protein biomarkers are provided. In particular, methods and systems for screening cervical cells for the expression of proteins, which occur as a result of premalignant cervical disease and progression to invasive cervical cancer. 1. A method of diagnosing or providing a prognosis for premalignant and malignant cervical disease in an individual , the method comprising the steps of:isolating proteins from cervical cytology samples;detecting two or more neoplastic protein biomarkers associated with cervical cancer in a biological sample from an individual;measuring the presence and/or the level of said biomarkers in the sample, andusing the presence and/or the levels of the biomarkers for diagnosing or a prognosis for premalignant and malignant cervical disease.2. The method of claim 1 , wherein the method comprises the detection of neoplastic biomarkers selected from any two or more of: p16ink4a claim 1 , Survivin claim 1 , HPV E6 claim 1 , HPV E7 claim 1 , LR67 claim 1 , Keratin 17 claim 1 , Keratin 7 claim 1 , Ki-67 claim 1 , ERK-1 claim 1 , or Telomerase.3. The method of or claim 1 , wherein the method comprises detecting the level of at least two neoplastic biomarkers by a method selected from the group consisting of an antibody based assay claim 1 , ELISA claim 1 , western blotting claim 1 , mass spectrometry claim 1 , protein microarray claim 1 , flow cytrometry claim 1 , immunofluorescence claim 1 , immunohistochemistry claim 1 , and a multiplex detection assay.4. The method of claim 3 , wherein the level of at least one neoplastic biomarker is detected by antibody based assay.5. The method of claim 3 , wherein the level of at least one neoplastic biomarker is detected by mass spectroscopy.6. The method of claim 3 , wherein the level of at least one neoplastic biomarker is detected by a multiplex assay.7. The method of claim 6 , wherein said multiplex ...

Подробнее
Номер записи: 34
24-01-2019 дата публикации

Novel peptides and combination of peptides for use in immunotherapy against various tumors

Номер: US20190023762A1
Автор: Andrea MAHR, Harpreet Singh, Jens FRITSCHE, Lea STEVERMANN, Oliver Schoor, Toni Weinschenk
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Подробнее
Номер записи: 35
23-01-2020 дата публикации

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES

Номер: US20200024672A1
Автор: De Jong Jan Cornelius, Fouchier Ronaldus Adrianus Maria, Groen Jan, Osterhaus Albertus Dominicus Marcellinus Erasmus, Van Den Hoogen Bernadetta Gerarda
Принадлежит:

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. 184.-. (canceled)85. A kit for determining the presence of metapneumovirus (MPV) in a mammalian subject , the kit comprising:a DNA probe of at least 10 nucleotides that specifically hybridizes to a target polynucleotide,wherein the DNA probe does not specifically hybridize to a polynucleotide from avian pneumovirus (APV);wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:374 and 376 or the complement of the sequence;wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA; andwherein the target polynucleotide comprises a first nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:375 or the complement of the first nucleic acid; orwherein the target ...

Подробнее
Номер записи: 36
24-01-2019 дата публикации

ENZYME-LINKED IMMUNOASSAY TO DETECT FELIS CATUS GAMMAHERPESVIRUS 1

Номер: US20190025306A1
Автор: Stutzman-Rodriguez Kathryn R., Troyer Ryan M., VandeWoude Susan
Принадлежит: Colorado State University Research Foundation, Inc .

Indirect ELISAs to detect exposure to gammaherpesvirus 1 (FcaGHV1) in domestic cats. These ELISAs detect feline serum antibodies to ORF52 and ORF38 of FcaGHV1. The ELISA assays are sensitive, specific, and adaptable for scale up use in high throughput diagnostics. 1Felis catus. A method of detecting antibodies to gammaherpesvirus 1 (FcaGHV1) in a test sample comprising the steps of:obtaining a test sample;contacting the test sample with recombinant FcaGHV1 ORF38 and ORF52 polypeptides or fragments thereof; anddetecting binding between antibodies to FcaGHV1 in the test sample and at least one of the recombinant FcaGHV1 polypeptides or fragments thereof, whereby the presence of binding between antibodies to FcaGHV1 in the sample and one of the recombinant FcaGHV1 polypeptides or fragments thereof is indicative of antibodies to FcaGHV1 in the test sample.2. The method of detecting antibodies to FcaGHV1 in a test sample according to wherein the test sample is a test sample from a feline.3. The method according to wherein the test sample is a test sample from a domestic cat.4. The method according to wherein the test sample is a blood claim 1 , serum or plasma sample from a domestic cat.5. The method according to wherein the detection assay is an IFA claim 1 , a western blot assay or an ELISA.6. The method according to wherein the detection assay is an indirect ELISA.7. The method of detecting antibodies to FcaGHV1 in a test sample according to further comprising the step of performing qPCR on the sample to screen for FcaGHV1 nucleic acid claim 1 , whereby the presence of FcaGHV1 nucleic acid in the test sample is indicative of an active infection with FcaGHV1 in the animal from which the test sample was obtained.8. The method of detecting antibodies to FcaGHV1 in a test sample according to further comprising:contacting the test sample with additional recombinant FcaGHV1 polypeptides or fragments thereof;detecting binding between antibodies to FcaGHV1 in the test sample ...

Подробнее
Номер записи: 37
23-01-2020 дата публикации

ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAME

Номер: US20200025759A1
Автор: IKEUCHI EMINA
Принадлежит:

The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains: 1. An antibody including an amino acid sequence , wherein the amino acid sequence includes , in an N- to C-direction , the following structural domains:{'br': None, 'N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C'} FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence;', 'the CDR1 includes an amino acid sequence represented by SEQ ID NO: 1;', 'the CDR2 includes an amino acid sequence represented by SEQ ID NO: 2; and', 'the CDR3 includes an amino acid sequence represented by SEQ ID NO: 3., 'wherein'}2. The antibody according to claim 1 , whereinthe antibody is capable of binding to an intramolecular protein of a type-A influenza virus.3. The antibody according to claim 1 , whereinthe antibody is a single-domain antibody.4. The antibody according to claim 1 , whereinthe type-A influenza virus is at least one selected from the group consisting of type-A influenza virus subtypes H1N1l(A/Hyogo/YS/2011 pdm), H1N1 (A/Hokkaido/6-5/2014 pdm), H5N1 (A/duck/Hokkaido/Vac-3/2007), H7N7 (A/duck/Hokkaido/Vac-2/2004), H1N1 (A/Puerto Rico/8/34/Mount Sinai), H1N1 (A/duck/Tottori/723/1980), H1N1 (A/swine/Hokkaido/2/81), H2N3 (A/duck/Hokkaido/17/01), H2N9 (A/duck/Hong Kong/278/78), H3N2 (A/duck/Hokkaido/5/77), H3N8 (A/duck/Mongolia/4/03), H4N6 (A/duck/Czech/56), H5N2 (A/duck/Pennsylvania/10218/84), H5N3 (A/duck/Hong Kong/820/80), 116N5 (A/shearwater/S. Australia/1/72), H7N2 (A/duck/Hong Kong/301/78), H7N7 (A/seal/Massachusetts/1/1980), H9N2 (A/duck/Hong Kong/448/78), H9N2 (A/turkey/Wisconsin/1966), H, 1N6 (A/duck/England/1/1956), and H12N5 (A/duck/Alberta/60/76).5. The antibody according to claim 1 , whereinthe FR1 includes the amino acid sequences represented by SEQ ID NO: 4;the FR2 includes the amino acid sequences represented by SEQ ID NO: 5;the FR3 includes ...

Подробнее
Номер записи: 38
01-02-2018 дата публикации

METHOD FOR ASSESSING RISK OF HUMAN CYTOMEGALOVIRUS ACTIVE INFECTION IN BODY AND RELATED KIT

Номер: US20180031556A1
Автор: GE Shengxiang, Huang Xi, LI Jinjie, LI Tingdong, Xia Ningshao, ZHANG JUN
Принадлежит:

The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore. 19-. (canceled)10. A method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection , comprising the following steps of:(1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and(2) comparing the level with a predetermined reference value;wherein, the HCMV protein is selected from pp150 and/or pp28; and if the level is below the reference value, the subject is determined to be at risk of developing HCMV active infection.11. The method of claim 10 , wherein the method is characterized by one or more of the following items:(a) the subject is human;(b) the body fluid sample is selected from blood, serum, plasma, urine and saliva;(c) the active infection is a primary infection by HCMV in a subject that has not been infected by HCMV, or, a re-infection by HCMV or activation of latent HCMV in a subject that has been infected by HCMV;(d) the level of the antibody against the HCMV protein in the body fluid sample is determined by immunologic assay;(e) the level refers to an antibody titer, and the reference value refers to a predetermined ...

Подробнее
Номер записи: 39
31-01-2019 дата публикации

CHEMICALLY ACTIVATED NANOCAPSID FUNCTIONALIZED FOR CANCER TARGETING

Номер: US20190031720A1
Автор: CHEN CHUN CHIEH, Cheng R. Holland, STARK MARIE, Xing Li
Принадлежит:

Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids. 1. A modified capsid protein comprising a portion of hepatitis E virus (HEV) open Reading Frame 2 (ORF2) protein that is able to form an acid and proteolytically stable HEV virus like particle (VLP) , wherein:the portion of HEV ORF2 comprises a P-domain of the HEV ORF2 protein;the P-domain comprises at least one surface variable loop and a C-terminus;the P-domain comprises a cysteine in the at least one surface variable loop or at the C-terminus; andthe HEV ORF2 portion retains its ability to form an acid and proteolytically stable HEV VLP when the surface variable loop or C-terminal cysteine is chemically derivatized.2. The modified capsid protein of claim 1 , wherein the HEV ORF2 portion retains its ability to form an acid and proteolytically stable HEV VLP when the surface variable loop or C-terminal cysteine is alkylated claim 1 , agitated claim 1 , arylated claim 1 , succinylated claim 1 , oxidized claim 1 , or conjugated to a detectable label or bioactive agent.3. The modified capsid protein of or claim 1 , wherein the modified capsid protein comprises an amino acid sequence at least 90% claim 1 , 95% claim 1 , or 99% identical claim 1 , or identical claim 1 , to residues 112-608 of the HEV ORF2 protein of SEQ ID NO:1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , or 6.4. The modified capsid ...

Подробнее
Номер записи: 40
31-01-2019 дата публикации

TRUNCATED GLYCOPROTEIN G OF HERPES SIMPLEX VIRUS 2

Номер: US20190031723A1
Автор: LILJEQVIST Jan-Åke
Принадлежит:

The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8. 1. A protein comprising a truncated version of the HSV-2 protein mgG-2 , said protein comprising:(i) an extracellular region of mgG-2 (EX-mgG-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3;(ii) a truncated transmembrane region of mgG-2 (t-TMR-mgG-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and(iii) an intracellular region of mgG-2 (IC-mgG-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or at least 95%, sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.2. The protein according to claim 1 , wherein the truncated ...

Подробнее
Номер записи: 41
31-01-2019 дата публикации

METHODS FOR UNIVERSAL TARGET CAPTURE

Номер: US20190032042A1
Автор: Dykes Colin
Принадлежит:

The invention generally relates to methods for universal target capture. 1. A method of isolating a microorganism in a sample , the method comprising:obtaining a sample suspected of containing at least one microorganism;introducing to the sample an agent that causes the microorganism to display an element;exposing the sample to a capture moiety that binds the element, thereby forming a capture moiety/microorganism complex; andisolating the capture moiety/microorganism complex from the sample.2. The method of claim 1 , wherein said sample comprises two or more microorganisms and the agent causes both microorganisms to display the same element.3. The method of claim 1 , wherein the agent is a bacteriophage.4. The method of claim 3 , wherein the element is a cell surface protein.5. The method of claim 4 , wherein the capture moiety is an antibody.6. The method of claim 3 , wherein said bacteriophage contains a biotinylation domain.7. The method of claim 6 , wherein the capture moiety comprises streptavidin.8. The method of claim 1 , wherein the microorganism is a bacteria.9. The method of claim 1 , wherein the microorganism is a fungus.10. The method of claim 1 , wherein the microorganism is present in the sample at as low as 1 CFU/mL.11. The method of claim 1 , wherein the capture moiety is bound to a magnetic particle.12. The method of claim 11 , wherein said isolating step applying a magnetic field.13. A method of isolating a plurality of targets in a sample claim 11 , the method comprising:obtaining a sample suspected of containing more than one target;introducing to the sample an agent that binds to more than one target in the sample;exposing the sample to a capture moiety that binds the agent, thereby forming capture moiety/target complexes; andisolating the capture moiety/target complexes from the sample. The present application claims the benefit of and priority to U.S. provisional patent application Ser. No. 61/739,567 filed Dec. 19, 2012, the content of which ...

Подробнее
Номер записи: 42
04-02-2021 дата публикации

Inverse Agonistic Anti-US28 Antibodies

Номер: US20210032316A1
Автор: Martine Joyce Smit, Raimond Heukers, Raymond Henry De Wit, Tian Shu Fan, Timo Werner Marcella De Groof
Принадлежит: Stichting VU

The invention relates to a novel class of antagonistic and inverse agonistic anti-US28 antibodies, more specifically to single heavy chain variable domain antibodies (VHH) and variants and modifications thereof. The invention further relates to methods for producing these antibodies and to the use of the antibodies in methods for diagnostic and therapeutic purposes, especially for treatment of an individual suffering from a CMV-positive tumor such as glioblastoma.

Подробнее
Номер записи: 43
30-01-2020 дата публикации

Bacteriophage-based electrochemical bacterial sensors, systems, and methods

Номер: US20200033340A1
Автор: Ramaraja P. Ramasamy, Yan Zhou
Принадлежит: University of Georgia Research Foundation Inc UGARF

The present disclosure includes methods and systems of detecting bacteria in a sample using phage-functionalized sensors, methods of enriching a sample with phage-functionalized magnetic particles, phage-functionalized magnetic particles and methods of making phage-functionalized magnetic particles.

Подробнее
Номер записи: 44
30-01-2020 дата публикации

Exosome-mediated diagnosis of hepatitis virus infections and diseases

Номер: US20200033343A1
Автор: Gale W. Newman, Sam Anyanwu
Принадлежит: Morehouse School of Medicine Inc

A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.

Подробнее
Номер записи: 45
05-02-2015 дата публикации

Bifunctional tumor diagnosis reagent and method for tumor diagnosis

Номер: US20150037817A1
Автор: Demin Duan, Di LU, Dongling Yang, Jing Feng, Kelong Fan, Minmin Liang, Xiyun Yan
Принадлежит: Institute of Biophysics of CAS

The invention relates to a bifunctional tumor diagnostic reagent and a method for tumor diagnosis. The reagent consists of a protein shell specifically recognizing a cancer tissue and/or a cancer cell and an inorganic nano-core having the catalytic activity of a peroxidase. The bifunctional tumor diagnostic reagent has two functions, i.e., tumor specific identification and color development, and enables the tumor specific identification and the color development to be completed in one step, and the operation of the process is simple and convenient.

Подробнее
Номер записи: 46
08-02-2018 дата публикации

RECOMBINANT HUMAN ANTIBODIES FOR THERAPY AND PREVENTION OF POLYOMAVIRUS-RELATED DISEASES

Номер: US20180037635A1
Автор: Combaluzier Benoit, GRIMM Jan, Jelcic Ivan, MARTIN Roland
Принадлежит:

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics. 129-. (canceled)30. A polynucleotide encoding at least a binding domain of a variable region of an immunoglobulin chain of a human monoclonal antibody or an antigen-binding fragment thereof capable of binding to a polyomavirus and/or antigen thereof.31. A vector comprising the polynucleotide of .32. The vector of claim 31 , further comprising a polynucleotide encoding at least a binding domain of a variable region of an immunoglobulin chain of a human monoclonal antibody or an antigen-binding fragment thereof capable of binding to a polyomavirus and/or antigen thereof claim 31 , wherein the polyomavirus is JC virus (JCV) or BK virus (BKV) claim 31 , wherein the polynucleotide further encodes the variable region of the other immunoglobulin chain of the antibody or an antigen-binding fragment thereof.33. A host cell comprising a polynucleotide of .34. A composition comprising a polynucleotide of .35. The composition of claim 34 , wherein the composition:(a) is a pharmaceutical composition and further comprises a pharmaceutical acceptable carrier, or(b) is a diagnostic composition, and further comprises reagents conventionally used in immune- or nucleic acid based diagnostic methods.36. The composition of claim 34 , further comprising an immunomodulatory agent.37. A kit useful in the diagnosis or monitoring of the progression of ...

Подробнее
Номер записи: 47
08-02-2018 дата публикации

KITS AND METHODS FOR PATHOGEN DETECTION

Номер: US20180037947A1
Автор: Broyles David, Daunert Sylvia, Deo Sapna, Kobetz Erin, Manfredi Anita
Принадлежит:

Kits and methods for detecting pathogens without the need for laboratory equipment are disclosed. The kits and methods described herein allow for near-room temperature amplification of pathogen polynucleotides in a biological sample in a one-compartment reaction vessel. The kits and methods may be used to detect any target nucleic acid, such as DNA or RNA from a bacterial, fungal, or viral pathogen. 1. A kit for detection of a pathogen polynucleotide in a biological sample comprising:(a) a reaction vessel comprising: (1) a padlock probe comprising a 5′ end complementary to a first section of the pathogen polynucleotide and a 3′ end complementary to a second section of the pathogen polynucleotide, wherein the first section and second section of the pathogen polynucleotide sequence are located adjacent to each other; (2) a ligase that anneals the 5′ and 3′ ends of the padlock probe together to form a circular padlock probe; (3) a primer comprising a polynucleotide complementary to a portion of the padlock probe; (4) a polymerase; and (5) a reporter probe;(b) a reaction buffer that supports polynucleotide ligation and polymerization; and(c) a test strip.2Chlamydia tracomatisNeisseria gonorrhoeae.. The kit of claim 1 , wherein the pathogen is selected from the group consisting of human papillomavirus claim 1 , claim 1 , and3. The kit of or claim 1 , wherein the padlock probe comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO:8 claim 1 , SEQ ID NO:9 claim 1 , SEQ ID NO:10 claim 1 , SEQ ID NO:14 claim 1 , SEQ ID NO:15 claim 1 , SEQ ID NO:16 claim 1 , SEQ ID NO:20 claim 1 , and a variant having at least 90% sequence identity to any of the foregoing.4. The kit of any of - claim 1 , wherein the padlock probe comprises the polynucleotide sequences of SEQ ID NO:3 and SEQ ID NO:4 claim 1 , SEQ ID NO:9 and SEQ ID NO:10 claim 1 , SEQ ID NO:15 and SEQ ID NO:16 claim 1 , or variants ...

Подробнее
Номер записи: 48
24-02-2022 дата публикации

MHC Class I Associated Hepatitis B Peptides

Номер: US20220054631A1
Автор: Philip Ramila
Принадлежит: Emergex Vaccines Holding Ltd.

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease. 1. A pharmaceutical composition comprising a polypeptide , oligopeptide or peptide consisting of 8 to about 30 amino acid residues and comprising a sequence that is selected from the group consisting of:(i) SEQ ID NO: 1, 3, and 5 to 17; and(ii) an amino acid sequence that differs from SEQ ID NO: 1, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 by no more than one amino acid unit;wherein said polypeptide, oligopeptide or peptide binds to one or more class I MHC alleles or can be processed to bind to one or more class I MHC alleles and activate a T lymphocyte.2. The pharmaceutical composition of wherein said polypeptide claim 1 , oligopeptide or peptide comprises at least two epitopic peptides.3. The pharmaceutical composition of wherein said polypeptide claim 1 , oligopeptide or peptide comprises at least three epitopic peptides.4. The pharmaceutical composition of wherein said polypeptide claim 1 , oligopeptide or peptide comprises at least four epitopic peptides.5. A polynucleotide selected from the group consisting of: (a) a polynucleotide that encodes an oligopeptide or peptide of claim 1 , and (b) the full complement of (a).6. The polynucleotide of claim 5 , wherein the polynucleotide of (a) is DNA.7. The polynucleotide of claim 5 , wherein the polynucleotide of (a) is RNA.8. A method for vaccinating and treating a subject for HBV infection claim 5 , said infected cells expressing any class I MHC molecule claim 5 , comprising administering to said subject a composition that binds to ...

Подробнее
Номер записи: 49
07-02-2019 дата публикации

MHC Class I Associated Hepatitis B Peptides

Номер: US20190038740A1
Автор: Philip Ramila
Принадлежит: Emergex Vaccines Holding Ltd.

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease. 1. An isolated oligopeptide or peptide in a pharmaceutical composition comprising at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 17 , said oligopeptide or peptide consisting of 8 to about 30 amino acid residues , wherein said oligopeptide or peptide binds to class I MEW molecules or can be processed to bind to class I MEW molecules and activate T lymphocyte response and wherein the oligopeptide or peptide is in the form of a pharmaceutically acceptable salt.2. The oligopeptide of wherein said oligopeptide comprises at least two epitopic peptides.3. The oligopeptide of wherein said oligopeptide comprises at least three epitopic peptides.4. The oligopeptide of wherein said oligopeptide comprises at least four epitopic peptides.5. The oligopeptide or peptide of wherein said oligopeptide or peptide differs from SEQ ID NO: 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 claim 1 , 9 claim 1 , 10 claim 1 , 11 claim 1 , 12 13 claim 1 , 14 claim 1 , 15 claim 1 , 16 or 17 wherein said difference is no more than one amino acid unit.6. The oligopeptide or peptide of wherein said one amino acid difference is the result of a conservative amino acid substitution.7. The oligopeptide or peptide of wherein said one amino acid difference is the substitution of one hydrophobic amino acid with another hydrophobic amino acid.8. The oligopeptide or peptide of wherein said amino acid difference is the addition or deletion ...

Подробнее
Номер записи: 50
06-02-2020 дата публикации

Near-infrared time-of-flight imaging using laser diodes with bragg reflectors

Номер: US20200037883A1
Автор: Mohammed N. Islam
Принадлежит: Omni Medsci Inc

A remote sensing system includes an array of laser diodes configured to generate light. One or more scanners are configured to receive a portion of the light from the array of laser diodes and to direct the portion of the light from the array of laser diodes to an object. A detection system is configured to receive at least a portion of light reflected from the object and is configured to be synchronized to the at least a portion of the array of laser diodes comprising Bragg reflectors. The remote sensing system is configured to generate a two-dimensional or three-dimensional mapping using at least a portion of a time-of-flight measurement. The remote sensing system is adapted to be mounted on a vehicle and communicate with a cloud. The at least a portion of the two-dimensional or three-dimensional mapping is combined with global positioning system information.

Подробнее
Номер записи: 51
12-02-2015 дата публикации

TARGET-SPECIFIC PROBE COMPRISING T7 BACTERIOPHAGE AND DETECTING FOR BIOMARKER USING THE SAME

Номер: US20150044665A1
Автор: CHOI Jong-Hoon, HWANG Mintai Peter, Lee Jong-Wook, LEE Kwan-Hyi, Seok Hyun-Kwang, SONG Jang-won
Принадлежит: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

The present invention relates to a target-specific probe containing T7 bacteriophage with a targeting antibody, and a detection method or a detection kit for a biomarker using the target-specific probe. The biomarker can be detected by using the genetically-modified T7 bacteriophage expressing various heterogeneous proteins and peptides on its surface and antibody-antigen specific reaction which can make the probe targeted to a biomarker or bacteria; and a detectable labeling agent, for example a quantum dot. 1. A target-specific probe including a binding peptide bound to a head part of T7 bacteriophage , a targeting antibody connected to the binding peptide , and a detectable labeling agent bound to a tail part of T7 bacteriophage.2. The target-specific probe according to claim 1 , wherein the binding peptide is protein G claim 1 , protein A claim 1 , protein A/G claim 1 , Fc receptor claim 1 , protein Z or a biotinylation tag.3. The target-specific probe according to claim 1 , wherein the targeting antibody is connected to the binding peptide through Fc part of the targeting antibody.4. The target-specific probe according to claim 1 , wherein the binding peptide is provided by a fusion peptide where the binding peptide is bound to a C-terminus of the head part of T7 bacteriophage.5. The target-specific probe according to claim 1 , wherein the targeting antibody is bound to the binding peptide via HIS Tag claim 1 , CYS Tag claim 1 , GST Tag or biotinylation binding tag.6. The target-specific probe according to claim 1 , wherein the labeling agent is bound to the tail part of T7 bacteriophage via HIS Tag claim 1 , CYS Tag claim 1 , GST Tag or biotinylation binding tag.7. The target-specific probe according to claim 6 , wherein the tag is inserted into the internal site in the tail part of T7 bacteriophage or connected to an end of the tail part of T7 bacteriophage.8. The target-specific probe according to claim 1 , wherein the T7 bacteriophage is an modified T7 ...

Подробнее
Номер записи: 52
12-02-2015 дата публикации

Methods for detection of anti-cytomegalovirus neutralizing antibodies

Номер: US20150044668A1
Автор: Barthelemy ONTSOUKA, David E. Anderson, Jasminka Bozic
Принадлежит: Variation Biotechnologies Inc

The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.

Подробнее
Номер записи: 53
16-02-2017 дата публикации

COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B

Номер: US20170042960A1
Автор: Geng Xin, Xue Ding
Принадлежит:

The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein. 1. A method for treating hepatitis B infection in a subject , said method comprising administering to a subject in need of such a treatment a composition (i) that is capable of inhibiting binding of hepatitis B virus X protein to a Bcl-2 family member protein in said subject; (ii) that is capable of reducing the expression of Bcl-2 family member protein in said subject; or (iii) a combination thereof.2. The method of claim 1 , wherein said Bcl-2 family member protein comprises Bcl-2 claim 1 , Bcl-xL claim 1 , an additional member claim 1 , or a combination thereof.3. The method of claim 1 , wherein said composition comprises a binding inhibitor that is capable of inhibiting binding of hepatitis B virus X protein to said Bcl-2 family member protein.4. The method of claim 3 , wherein said binding inhibitor is capable of interacting with Bcl-2 homology 3 (BH3)-like motif of hepatitis B virus X protein or a Bcl-2 family member.5. The method of claim 1 , wherein said composition comprises an expression inhibitor that is capable of reducing the expression of Bcl-2 family member protein.6. The method of claim 5 , wherein said expression inhibitor is a siRNA or a small RNA that is capable of reducing the expression of Bcl-2 claim 5 , Bcl-xL claim 5 , or a combination thereof.7. A method for reducing replication of ...

Подробнее
Номер записи: 54
16-02-2017 дата публикации

NOVEL METHODS, BIOASSAYS, AND BIOMARKERS FOR HPV-RELATED CONDITIONS

Номер: US20170045515A1
Автор: Anderson Karen, LaBaer Joshua, Posner Marshall
Принадлежит:

Provided herein are methods for the rapid detection of HPV types, such as HPV 16- and HPV18-specific antibodies, in patient samples that contain antibodies. For example, patients with head and neck cancers have detectable antibodies to multiple early genes derived from HPV. These antibodies also are useful as biomarkers for HPV-associated malignancies and premalignant states, for diagnosis and prognosis, and for methods of assessing treatment and cancer-recurrence prediction. 1. A method for detection of HPV , comprising the steps of:contacting a sample containing antibodies from a patient with an in vitro transcribed and translated protein from HPV; andcomparing a patterns of HPV antibody bound to the protein with a control for a HPV-associated condition.2. The method of claim 1 , wherein the HPV-associated condition comprises one or more of head and neck cancers or premalignant growths.3. The method of claim 2 , wherein the HPV-associated condition comprises an oropharyngeal carcinoma (OPC).4. The method of claim 1 , wherein the protein comprises one or more of HPV16 E1 claim 1 , NE2 claim 1 , CE2 claim 1 , E4 claim 1 , E6 claim 1 , E7 claim 1 , and L1.5. The method of claim 1 , wherein the protein comprises one or more of HPV18 E1 claim 1 , E2 claim 1 , and L1.6. The method of claim 1 , wherein more than one protein from HPV is utilized with the sample.7. The method of claim 1 , wherein the sample is selected from the group consisting of blood sample claim 1 , serum sample claim 1 , and oral rinse sample.8. A substrate including at least one in vitro transcribed and translated protein from HPV as a part of a diagnostic claim 1 , prognostic claim 1 , predictive or monitoring assay for an HPV-associated condition.9. A method for detection of HPV claim 1 , comprising the steps of:contacting a sample containing antibodies from a patient with an in vitro transcribed and translated protein from HPV;comparing a patterns of HPV antibody bound to the protein with a ...

Подробнее
Номер записи: 55
03-03-2022 дата публикации

CHARACTERIZATION OF ADENO-ASSOCIATED VIRUS USING MICROCHIP CAPILLARY ELECTROPHORESIS

Номер: US20220065868A1
Автор: Jiang Bowen, Liu Dingjiang, Tzul Franco
Принадлежит:

Methods and systems for identifying capsid viral proteins in a sample containing viral vectors are provided, including determining the ratio of the capsid viral proteins of adeno-associated virus. The methods and systems comprise denaturing the capsid viral proteins in the sample, labeling the denatured capsid viral proteins with a lysine-conjugation dye, generating a separation profile of the denatured/labeled capsid viral proteins using microchip capillary electrophoresis, quantifying levels of the capsid viral proteins based on the separation profile, determining a quantification ratio of the capsid viral proteins based on the separation profile, and normalizing the quantification ratio based on lysine contents of the capsid viral proteins.

Подробнее
Номер записи: 56
14-02-2019 дата публикации

Classification and Treatment of Gastric Cancer

Номер: US20190049453A1
Автор: Duda Gabriel Dan, Lauwers Gregory Y.
Принадлежит:

Protein and mRNA expression based methods for classification of gastric cancer, and methods of treatment based thereon. 1. A method comprising:providing a sample comprising tissue comprising tumor cells from a gastric tumor; and (i) Epstein Barr Virus in the tumor cells;', '(ii) DNA mismatch repair protein expression in the tumor cells;', '(iii) E-cadherin protein expression in the tumor cells;', '(iv) p53 protein expression in the tumor cells; and', '(v) Mucin protein expression in the tumor cells., 'determining in tumor cells in the sample2. A method of categorizing a gastric tumor in a subject , the method comprising:providing a sample comprising tissue comprising tumor cells from a gastric tumor; and (i) a level of Epstein Barr Virus (EBV) in the tumor cells, preferably a nuclear level of EBV;', '(ii) DNA mismatch repair protein expression in the tumor cells;', '(iii) E-cadherin protein expression in the tumor cells;', '(iv) p53 protein expression in the tumor cells; and', '(v) Mucin protein expression in the tumor cells; and, 'determining in tumor cells in the samplecategorizing a tumor with EBV, preferably nuclear EBV, above a reference level, and optionally with prominent lymphoid infiltrate, in group 1;categorizing a tumor with a nuclear DNA mismatch repair protein expression below a reference level in group 2;categorizing a tumor with E-cadherin expression below a reference level, or only cytoplasmic E-cadherin expression, in group 3;categorizing a tumor with normal p53 expression and cytoplasmic mucin expression above a reference level in group 4; andcategorizing a tumor with aberrant levels of p53 expression and normal levels of mucin expression in group 5.3. The method of claim 1 , wherein the level of Epstein Barr Virus is determined using EBER in situ hybridization (EBER-ISH) claim 1 , and/or the DNA mismatch repair protein expression; E-cadherin expression; p53 expression; and Mucin expression is detected using immunohistochemistry in intact tumor ...

Подробнее
Номер записи: 57
25-02-2021 дата публикации

Method for the detection of a binding partner of a multispecific binder

Номер: US20210055304A1
Автор: Kay-Gunnar Stubenrauch, Uwe Wessels
Принадлежит: Hoffmann La Roche Inc

Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.

Подробнее
Номер записи: 58
22-02-2018 дата публикации

Flow cytometry method for evaluating biological material for unassociated virus-size particles of influenza virus viral type

Номер: US20180052163A1
Автор: Francis Kevin KOHLMEIER, Michael A. ARTINGER, Michael W. OLSZOWY, Tyler Donald GATES
Принадлежит: Intellicyt Corp

A method for evaluating a biological material for unassociated virus-size particles having a particular epitope uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent anti body stain.

Подробнее
Номер записи: 59
10-03-2022 дата публикации

DNA APTAMERS SPECIFIC OF ADENOVIRUS TYPES

Номер: US20220073920A1
Автор: JOURDAN Samuel, MULHOLLAND Catherine, OGORZALY Leslie
Принадлежит:

A single stranded nucleic acid aptamer able to specifically bind to at least one Adenovirus type, the aptamer comprising or consisting of one of sequences SEQ ID NO:1 to 3, or variants thereof having at least 50% sequence identity. Additionally, a composition comprising the aptamer. Furthermore, use of the aptamer, for detecting, capturing, concentrating and/or quantifying at least one Adenovirus type. Still further, in vitro methods for capturing, detecting and/or quantifying at least one Adenovirus type. Further yet, a kit for detecting, quantifying, capturing and/or concentrating at least one Adenovirus type. 114.-. (canceled)15. A single stranded nucleic acid aptamer able to specifically bind to at least one Adenovirus type , said aptamer comprising at least one of sequences SEQ ID NO:1 to 3 , or variants thereof having at least 50% sequence identity.16. A composition comprising at least one single stranded nucleic acid aptamer able to specifically bind to at least one Adenovirus type , said aptamer comprising at least one of sequences SEQ ID NO:1 to 3 or variants thereof having at least 50% sequence identity and at least one Adenovirus type.17. An In vitro method for capturing at least one Adenovirus type in a sample , comprising the step of contacting the sample with a single strand nucleic acid aptamer able to specifically bind to at least one Adenovirus type , said aptamer comprising at least one of sequences SEQ ID NO:1 to 3 or variants thereof having at least 50% sequence identity.18. An In vitro method for at least one of detecting and quantifying at least one Adenovirus type in a sample , comprising:in vitro capturing of at least one Adenovirus type in a sample by contacting the sample with a single strand nucleic acid aptamer able to specifically bind to at least one Adenovirus type, said aptamer comprising at least one of sequences SEQ ID NO:1 to 3 or variants thereof having at least 50% sequence identity;one of quantifying or detecting one of the ...

Подробнее
Номер записи: 60
10-03-2022 дата публикации

SELECTIVE DETECTION OF NOROVIRUS

Номер: US20220074001A1
Автор: Barclay Leslie, Chhabra Preeti, Gregoricus Nicole, Vinje Jan
Принадлежит:

A process for detecting norovirus nucleic acid in a sample is provided including producing an amplification product by amplifying a norovirus nucleotide sequence using a forward primer of SEQ ID NO: 1, 4, or 10 and a reverse primer of SEQ ID NO: 2, 5, or 11, and detecting the amplification product to detect norovirus in the sample. Also provided are reagents and methods for detecting and distinguishing GI or Gil norovirus from other infectious agents. A kit is provided for detecting and quantifying norovirus in a sample. 148.-. (canceled)49. A kit for detecting norovirus infection in a subject comprising: a forward primer comprising a sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 4 , SEQ ID NO: 7 , SEQ ID NO: 10 , or any combination of said forward primers; a reverse primer comprising a sequence selected from the group consisting of SEQ ID NO: 2 , SEQ ID NO: 5 , SEQ ID NO: 8 , SEQ ID NO: 11 , or any combination of said reverse primers; and a probe having a label attached thereto.50. The kit of wherein said probe comprises a sequence selected from the group consisting of SEQ ID NO: 3 claim 49 , SEQ ID NO: 6 claim 49 , SEQ ID NO: 9 claim 49 , SEQ ID NO: 12 claim 49 , or any combination of said probes.51. The kit of claim 49 , wherein said label is selected from the group consisting of 6-carboxyfluorcein claim 49 , an indocarbocyanine fluorophore claim 49 , a 6-carboxyhexafluorcein fluorophore claim 49 , TAMRA claim 49 , AlexaFluor dyes such as AlexaFluor 495 or 590 claim 49 , Cascade Blue claim 49 , Marina Blue claim 49 , Pacific Blue claim 49 , Oregon Green claim 49 , Rhodamine claim 49 , Fluoroscein claim 49 , TET claim 49 , HEX claim 49 , Cy5 claim 49 , Cy3 claim 49 , Tetramethylrhodamine claim 49 , and any combination thereof.52. The kit of claim 51 , wherein said label is selected from the group consisting of a 6-carboxyfluorcein claim 51 , an indocarbocyanine fluorophore claim 51 , a 6-carboxyhexafluorcein fluorophore claim 51 , and ...

Подробнее
Номер записи: 61
21-02-2019 дата публикации

Methods Of Propagating Rhinovirus C In Previously Unsusceptible Cell Lines

Номер: US20190055521A1
Автор: Bochkov Yury A., Gern James E., Palmenberg Ann C.
Принадлежит:

The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided. 1. A kit comprising:a. at least one host cell able to support rhinovirus C replication, wherein the host cell comprises a heterologous CDHR3 receptor; andb. a sample of rhinovirus C or rhinovirus C variant.2. The kit of wherein the host cell is selected from the group consisting of NCI-H358 claim 1 , WI-38 claim 1 , WisL claim 1 , HEK293T claim 1 , BEAS-2B claim 1 , A549 and HeLa.3. The kit of wherein the CDHR3 receptor is a CDHR3-CY variant.4. A kit comprising:a. a nucleic acid encoding a CDHR3 receptor; andb. a sample of rhinovirus C.5. The kit of wherein the CDHR3 receptor is a CDHR3-CY variant.6. A host cell infected with rhinovirus C or rhinovirus C variant claim 4 , wherein the host cell has been modified to express an effective amount of a CDHR3 receptor and support propagation of rhinovirus C.7. The host cell of wherein the CDHR3 receptor is a CDHR3-CY variant.8. The transfected cell of wherein the host cell is a cell able to support rhinovirus C replication. This application is a divisional of U.S. patent application Ser. No. 14/836,327, filed Aug. 26, 2015, which claims the benefit of U.S. Provisional Patent Application 62/043,517, filed Aug. 29, 2014, and U.S. Provisional Patent Application 62/203,603, filed Aug. 11, 2015.This invention was made with government support under AI104317 awarded by the National Institutes of Health. The government has certain rights in the invention.The application includes the sequence listing that is concurrently filed in computer readable form. This sequence listing is incorporated ...

Подробнее
Номер записи: 62
01-03-2018 дата публикации

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES

Номер: US20180057894A1
Автор: De Jong Jan Cornelius, Fouchier Ronaldus Adrianus Maria, Groen Jan, Osterhaus Albertus Dominicus Marcellinus Erasmus, Van Den Hoogen Bernadetta Gerarda
Принадлежит: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM

Provided is an isolated mammalian negative strand RNA virus, (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. 184.-. (canceled)85metapneumovirus. A kit for determining the presence of (MPV) in a mammalian subject , the kit comprising:a DNA probe of at least 10 nucleotides that specifically hybridizes to a target polynucleotide,{'i': 'pneumovirus', 'wherein the DNA probe does not specifically hybridize to a polynucleotide from avian (APV);'}wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:322 and 323 or the complement of the sequence;wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA; andwherein the target polynucleotide comprises a first nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:324 or the complement of the first nucleic acid; orwherein the target polynucleotide comprises a ...

Подробнее
Номер записи: 63
03-03-2016 дата публикации

Norovirus detection sensor and electrochemical sensing method using the same

Номер: US20160061834A1
Автор: Du-Woon Kim, Heemin Lee, Jong-Soon Choi, Joseph Kwon, Sung Yang, Sung-A HONG
Принадлежит: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY, INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY, Korea Basic Science Institute KBSI

Disclosed herein are a norovirus detection sensor and an electrochemical sensing method using the sensor. Specifically, in the norovirus detection sensor including a bioreceptor and a signal detector, a three-dimensional gold nanosurface electrode is used as a substrate, and the bioreceptor employs concanavalin A as a sample capture agent immobilized to the substrate and capable of binding to norovirus. Therefore, the norovirus detection sensor has improved sensitivity by employing the three-dimensional gold nanosurface electrode having a wide surface area. In addition, the norovirus detection sensor has effects of reducing manufacturing costs using a non-antibody material, i.e., concanavalin A which is inexpensive and readily available.

Подробнее
Номер записи: 64
03-03-2016 дата публикации

IDENTIFICATION AND CHARACTERIZATION OF A PEPTIDE AFFINITY REAGENT FOR THE DETECTION OF NOROVIRUSES IN CLINICAL SAMPLES

Номер: US20160061835A1
Автор: Ajami Nadim Jose, Atmar Robert Legare, Estes Mary K., Palzkill Timothy Gerald, Rogers Jennifer Dawn
Принадлежит:

Embodiments of the disclosure include methods and/or compositions for the detection of viral infection, including at least infection. In particular embodiments, there are methods and/or compositions employing particular peptides and/or phage useful for detecting in a sample. The sample may be from an environment or from an individual. The individual may be a mammal, including a human, cow, horse, dog, cat, pig, and so forth. Certain exemplary peptides and phage that express the peptides are identified as useful for binding to . Such peptides and phage are provided to one or more samples in order to identify whether or not is present in the sample. 1. A composition comprising one or both of:a peptide comprising a sequence selected from the group consisting of the sequences in Table 1, or a functionally active variant thereof; anda phage that encodes the peptide or the variant.2. The composition of claim 1 , wherein the peptide is no more than about 50 amino acids in length.3. The composition of claim 1 , wherein the functionally active variant comprises one claim 1 , two claim 1 , or three or more alterations in SEQ ID NO:1.4. The composition of claim 3 , wherein the alterations are conservative amino acid substitutions.5. The composition of claim 1 , wherein the functionally active variant comprises sequence that is 80% claim 1 , 85% claim 1 , 90% claim 1 , 95% claim 1 , 97% claim 1 , 98% claim 1 , or 99% identical to the peptide of which it is a variant.6. The composition of claim 1 , wherein the peptide is labeled.7. The composition of claim 6 , wherein the label is fluorescent claim 6 , radioactive claim 6 , or colored.8. A composition comprising an antibody that recognizes a composition of .9Norovirus. A method of identifying in a sample claim 1 , comprising the step of subjecting the sample to the composition of .10NorovirusNorovirus. The method of claim 9 , wherein the subjecting step comprises binding of the peptide to the to produce a peptide/complex.11. The ...

Подробнее
Номер записи: 65
03-03-2016 дата публикации

LIPIDOMIC BIOMARKERS

Номер: US20160061849A1
Автор: Dwek Raymond A., Laing Peter, POLLOCK Stephanie, Zitzmann Nicole
Принадлежит:

Lipidomic markers for Hepatitis C and related conditions, treat hepatic fibrosis and hepatocellular carcinoma. An agent administered to such subject may be an cellular total fatty-acid content under iminosugar, which may be effective against hepatitis C. Such iminosugar may be, for example, one of N-substituted deoxynojrimycins and pharmaceutically acceptable salts thereof, N-substituted deoxygalactonojirimycins and pharmaceutically acceptable salts thereof and N-substituted Me-deoxygalactonojirimycins and pharmaceutically acceptable salts thereof. A method of assessing a Hepatitis C infection or a condition caused by or associated with said infection. This method comprises: obtaining a biological sample from a subject in need thereof; determining a level of at least one Hepatitis C lipidomic biomarker in said biological sample; and comparing said level of with a control level of said Hepatitis C lipidomic biomarker to assess the Hepatitis C infection or the condition caused by or associated with said infection in the subject. 1. A method of assessing a Hepatitis C infection or a condition caused by or associated with said infection , said method comprising:(a) obtaining a biological sample from a subject in need thereof;(b) determining a level of at least one Hepatitis C lipidomic biomarker in said biological sample; and(c) comparing said level of (b) with a control level of said Hepatitis C lipidomic biomarker to assess the Hepatitis C infection or the condition caused by or associated with said infection in the subject.2. The method of claim 1 , wherein said biological sample is a serum sample of the subject or a plasma sample of the subject.3. The method of claim 1 , wherein the subject is a human being.4. The method of claim 1 , wherein said determining said level comprises determining an abundance of Mead acid in said biological sample claim 1 , wherein a lower value of the determined abundance compared to a control abundance value indicates that the subject ...

Подробнее
Номер записи: 66
20-02-2020 дата публикации

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA

Номер: US20200056221A1
Автор: McCrea Keith R., Ward Robert S.
Принадлежит:

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods. 1. A method for concentrating a pathogen present in a biological sample obtained from a subject who is suspected of being infected with said pathogen , the method comprising:(a) contacting the biological sample obtained from the subject with an adsorption media under conditions to form an adhering complex comprising the adsorption media and said pathogen;(b) separating the adhering complex from components of the sample that are not included in the complex while maintaining the complex; and(c) collecting pathogens of the adhering complex.2. The method of claim 1 , wherein the biological sample is selected from the group consisting of whole blood claim 1 , serum claim 1 , plasma claim 1 , urine claim 1 , feces claim 1 , sputum claim 1 , tears claim 1 , saliva claim 1 , bronchial lavage fluid claim 1 , other bodily fluid claim 1 , and combinations thereof.3. The method of claim 2 , wherein the biological sample is a whole blood sample.4. The method of claim 2 , wherein (i) the whole blood sample is returned back to the subject before step (b) of claim 2 , and (ii) an additional whole blood sample is used to repeat step (a) claim 2 , to contact the additional whole blood sample on the adsorption media to thereby concentrate the pathogen.5. The method of claim 4 , wherein steps (i) and (ii) can be repeated 1 claim 4 , 2 claim 4 , 3 claim 4 , 4 claim 4 , 5 claim 4 , 6 or even more ...

Подробнее
Номер записи: 67
02-03-2017 дата публикации

Identification of JC viral epitopes by cytotoxic T lymphocytes in healthy individuals and their use in assays

Номер: US20170059568A1
Автор: Stuyver Lieven Jozef
Принадлежит:

The invention relates to a method to predict the onset and/or development of PML in a patient or in an immunosuppressed patient by detection of JCV specific CTL's in blood of said patient using any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other. 1. Method to predict the onset and/or development of PML in a patient by detection of JCV specific CTL's in blood of said patient using any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other.2. Method to predict the onset and/or development of PML in an immunosuppressed patient by detection of JCV specific CTL's in blood of said patient using any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other.3. Use of any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other to detect JCV specific CTL's in blood of a patient to predict the onset and/or development of PML.4. Use of any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other to detect JCV specific CTL's in blood of a immunosuppressed patient to predict the onset and/or development of PML. The detection of JCPyV (JC polyomavirus) reactive cytotoxic T lymphocytes in peripheral blood has been associated with a favorable outcome in patients with progressive multifocal leucoencephalopathy. The frequency of these cells in peripheral blood mononuclear cells of healthy volunteers is unknown. To help the development of a highly sensitive assay for detecting cellular immune responses against JC virus, according to the current invention a CTL prediction and mapping study of the whole JCPyV genome has been performed. A total of 98 peptides were selected, and subsequently tested in the 10 most common allotypes. Immune responses were evaluated in an optimized direct ex vivo ELISPOT assay, using 5*108+-enriched peripheral blood mononuclear cells ...

Подробнее
Номер записи: 68
02-03-2017 дата публикации

Blood sample analyzing method, blood sample analyzer, and system

Номер: US20170059593A1
Автор: Junki HAYASAKI
Принадлежит: Sysmex Corp

Disclosed is a blood sample analyzing method including preparing a measurement specimen by mixing a blood sample with a measuring reagent of fibrin and a fibrinogen degradation product (FDP); acquiring, based on a time-dependent change in optical information obtained by optically measuring the measurement specimen, first information indicating an FDP concentration and second information indicating a curving degree of a time course curve showing the time-dependent change of the optical information; and determining an enhanced fibrinolytic state of the blood sample or acquiring a value related to a D dimer of the blood sample based on the first information and the second information.

Подробнее
Номер записи: 69
05-03-2015 дата публикации

Facile laboratory method for localising biomolecules to the surface of cells and viruses

Номер: US20150064690A1
Автор: Nikolai Vladimirovich Bovin, Stephen Micheal Henry
Принадлежит: Kode Biotech Ltd

A facile method of localising sulfhydryl (—SH) group containing biomolecules, in particular peptides, to the membranes of living cells and enveloped viruses and a kit for use in a biological laboratory in accordance with the method.

Подробнее
Номер записи: 70
05-03-2015 дата публикации

POLYOMAVIRUS PEPTIDE SEQUENCES

Номер: US20150065367A1
Автор: Stuyver Lieven Jozef
Принадлежит:

The current invention concerns the identification of B-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay. 1. Human polyoma virus peptide sequences possessing an activity towards human antibodies in human samples.2. Human polyoma virus peptide sequences according to having any of the sequences as indicated in Table 11 to Table 18.3. Human polyoma virus peptide sequences according to having any of the sequences as indicated in Table 9.4. Use of human polyoma virus peptide sequences according to or for immune diagnostic purposes.5. Use of human polyoma virus peptide sequences according to for B-cell epitope studies.6. The use of human polyoma virus peptide sequences according to for B-cell stimulation and B-cell functionality studies.7. A device comprising a human polyoma virus peptide sequence according to or .8. Use of human polyoma viral small T antigen for immune response diagnostic purposes. The current invention relates to the identification of B-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay.Progressive multifocal leukoencephalopathy (PML) is a rare but often fatal brain disease caused by reactivation of the polyomavirus JC. The monoclonal antibodies natalizumab, efalizumab, and rituximab—used for the treatment of multiple sclerosis, psoriasis, hematological malignancies, Crohn's disease, and rheumatic diseases—have been associated with PML. Worldwide 181 (as of November 2011) cases of natalizumab-associated PML have been reported. International studies and standardization of methods are urgently needed to devise strategies to mitigate the risk of PML in natalizumab-treated patients.A new set of assay developments could lead to a better understanding of the virus reactivation, and that could lead to safe use of immune modulating agents (e.g. a Tysabri® (natalizumab)) and an optimized treatment algorithm.The human neurotropic ...

Подробнее
Номер записи: 71
17-03-2022 дата публикации

AGENT FOR PROMOTING EXPRESSION OF N-ACETYLGALACTOSAMINYLTRANSFERASE CONTAINING EXTRACT FROM INFLAMED TISSUES INOCULATED WITH VACCINIA VIRUS

Номер: US20220079995A1
Автор: Naiki Mitsuru, NAKAI Tomoko, SAKAI Daisuke, SHIBAYAMA Yoji
Принадлежит:

An object of the present invention is to provide an agent for promoting expression of N-acetylgalactosaminyltransferase that contains an extract from inflamed tissues inoculated with vaccinia virus. The present invention demonstrated that the extract from inflamed tissues inoculated with vaccinia virus promotes the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. Thus, the extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract is useful as an agent for promoting the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. 1. A method for determining or evaluating an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract , wherein the action of promoting expression of an N-acetylgalactosaminyltransferase in intervertebral disc cells is used as an index.2. The method according to claim 1 , wherein the N-acetylgalactosaminyltransferase is N-acetylgalactosaminyltransferase 1.3. The method according to claim 1 , wherein the N-acetylgalactosaminyltransferase is N-acetylgalactosaminyltransferase 2.4. The method according to claim 1 , comprisingcomparing expression increase rates between the N-acetylgalactosaminyltransferase 1 and the N-acetylgalactosaminyltransferase 2, andconfirming that the N-acetylgalactosaminyltransferase 1 has a higher expression increase rate.5. The method according to claim 1 , wherein the inflamed tissues are inflamed skin tissues of rabbits.6. A method for verifying that the extract from inflamed tissues inoculated with vaccinia virus or the preparation satisfies the quality standard by performing the determination or evaluation of .7. The method according to claim 6 , wherein the preparation is an injectable preparation or an oral preparation. This application is a division of U.S. application Ser. No. 16/279,341, filed Feb. 19, 2019, the contents of which are incorporated herein by reference.The present ...

Подробнее
Номер записи: 72
27-02-2020 дата публикации

ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS, ASSOCIATED VIRAL PARTICLES AND THERAPEUTIC FORMULATIONS COMPRISING THE SAME

Номер: US20200061161A1
Автор: BUNTING STUART, Colosi Peter Cameron, Pungor Erno
Принадлежит:

The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof. 1. A pharmaceutical formulation comprising a recombinant AAV FVIII virus , a buffering agent , an isotonicity agent , a bulking agent and a surfactant.2. The pharmaceutical formulation of claim 1 , wherein the recombinant AAV FVIII virus is AAV5-FVIII-SQ.3. The pharmaceutical formulation of or which is stable during storage at ≤65° C. for at least 2 weeks.4. The pharmaceutical formulation of any one of - claim 1 , which comprises sodium phosphate claim 1 , dibasic at a concentration of from about 0.1 mg/ml to about 3 mg/ml claim 1 , sodium phosphate monobasic monohydrate at a concentration of from about 0.1 mg/ml to about 3 mg/ml claim 1 , sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml claim 1 , mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml claim 1 , and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml.5. The pharmaceutical formulation of any one of - claim 1 , which comprises sodium phosphate claim 1 , dibasic at a concentration of about 1.42 mg/ml claim 1 , sodium phosphate monobasic monohydrate at a concentration of about 1.38 mg/ml claim 1 , sodium chloride at a concentration of about 8.18 mg/ml claim 1 , mannitol at a concentration of about 20 mg/ml claim 1 , and poloxamer 188 at a concentration of about 2 mg/ml.6. The pharmaceutical formulation of any one of - which is liquid.7. The pharmaceutical formulation of any one of - which comprises said AAV FVIII virus at a concentration of from ...

Подробнее
Номер записи: 73
17-03-2022 дата публикации

COMPOSITIONS AND METHODS FOR URINE SAMPLE STORAGE AND DNA EXTRACTION

Номер: US20220081705A1
Автор: CHEN Yiyou, Liu Gang, LU Ning, Wu Yang
Принадлежит:

The present disclosure provides compositions and methods for storing a biological sample, such as a urine sample. DNA molecules in a biological sample mixed with a storage reagent of the present disclosure can be kept stable for a surprisingly long time. In addition, also provided are compositions and methods for extracting DNA from a biological sample, such as a urine sample. Compared to commercialized products, compositions and methods of the present disclosure are more effective for DNA extraction, suitable for DNA extraction of large urine samples and easy to realize automatic DNA extraction. 1. A composition for storing a urine sample obtained from a subject , wherein the composition comprises a pH buffer , a chelating agent , and a surfactant.2. The composition of claim 1 , wherein the pH buffer is configured to adjust a pH of the composition to within a preselected range.3. The composition of claim 1 , wherein the pH buffer comprises acetic acid and a salt of acetic acid.4. The composition of claim 3 , wherein the salt of acetic acid is sodium acetate.5. The composition of claim 2 , wherein the preselected range of pH is about 5.0 to 6.5.6. The composition of claim 5 , wherein the pH of the composition is about 6.0.7. The composition of claim 4 , wherein the sodium acetate has a concentration of about 0.5 to 1.0 mol/L.8. The composition of claim 1 , wherein the chelating agent is an aminopolycarboxylic acid.9. The composition of claim 8 , wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA).10. The composition of claim 8 , wherein the EDTA has a concentration of about 10 to 25 mmol/L.11. The composition of claim 1 , wherein the surfactant is an anionic surfactant.12. The composition of claim 11 , wherein the anionic surfactant is a salt of dodecyl hydrogen sulfate.13. The composition of claim 11 , wherein the salt is a sodium salt claim 11 , and the anionic surfactant is sodium docecyl sulfate (SDS).14. The composition of claim 1 , wherein ...

Подробнее
Номер записи: 74
27-02-2020 дата публикации

ANTIBODY CAPABLE OF BINDING TO NOROVIRUS, COMPOSITE, DETECTION DEVICE AND METHOD USING THE SAME

Номер: US20200062828A1
Автор: YUGAWA KEIKO
Принадлежит:

Provided is a dimer antibody including two structural domains independently each represented by the following amino acid sequence, in an N- to C-direction, 2. The dimer antibody according to claim 1 , wherein the norovirus is a GII/4 norovirus.3. The dimer antibody according to claim 1 , whereinany one of the following requirements (iv)-(vi) is satisfied,Requirement (iv):the FR1 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 18-SEQ ID NO: 23,the FR2 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 24-SEQ ID NO: 28,the FR3 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 29-SEQ ID NO: 34,andthe FR4 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 35-SEQ ID NO: 37;Requirement (v):the FR1 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 18-SEQ ID NO: 23 has/have been substituted, deleted, or added,the FR2 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 24-SEQ ID NO: 28 has/have been substituted, deleted, or added,the FR3 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 29-SEQ ID NO: 34 has/have been substituted, deleted, or added, andthe FR4 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 35-SEQ ID NO: 37 has/have been substituted, deleted, or added; andRequirement (vi):the FR1 includes any one of the amino acid sequence represented by SEQ ID NO: 18-SEQ ID NO: 23,the ...

Подробнее
Номер записи: 75
12-03-2015 дата публикации

ANTIBODIES AND METHOD FOR DETERMINING DELETIONS IN HBV PRE-S2 REGION

Номер: US20150072885A1
Автор: HUANG WENYA, LEE Yun-Ping, SU Ih-Jen
Принадлежит:

A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-Sdeletion mutant LHBS using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-Sdeletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-Sdeletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis. 1. A large hepatitis B virus surface protein-specific antibody , specifically binding to a recombinant protein shown as the amino acid sequence of SEQ ID NO: 1.2. The antibody of claim 1 , wherein the antibody is produced by the hybridoma cell line deposited on Sep. 1 claim 1 , 2014 under accession number BCRC960490 at the Food Industry Research and Development Institute claim 1 , 331 Shih-Pin Road claim 1 , Hsinchu 300 claim 1 , Taiwan claim 1 , and also on Oct. 31 claim 1 , 2014 under accession number DSM ACC3253 at Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) claim 1 , Inhoffenstr. 7B claim 1 , 38124 Braunschweig claim 1 , Germany.3. The antibody of claim 2 , wherein the hybridoma cell line is fused by myeloma cells and splenocyte of mice immunized with the recombinant protein shown as the amino acid sequence of SEQ ID NO: 1.4. The antibody of claim 2 , wherein the antibody is an antigen-binding fragment or a functional variant of the large hepatitis B ...

Подробнее
Номер записи: 76
11-03-2021 дата публикации

Methods and Systems for the Rapid Detection of Microorganisms Using Recombinant Infectious Agents to Express an Indicator Subunit

Номер: US20210071225A1
Автор: Anderson Dwight L., Erickson Stephen E., Gil Jose S., Hahn Wendy
Принадлежит:

Disclosed herein are methods and systems for rapid detection of microorganisms such as bacteria in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of a particular bacteria of interest and an indicator signal may be amplified to optimize assay sensitivity. 1. A recombinant indicator bacteriophage comprising an indicator gene inserted into the bacteriophage genome , wherein the indicator gene encodes a peptide or polypeptide subunit of an indicator protein.2. The recombinant bacteriophage of further comprising a protease cut site.3. The recombinant bacteriophage of claim 1 , wherein the peptide or polypeptide subunit is a first subunit and is complementary to a second polypeptide subunit of the indicator protein.4. The recombinant bacteriophage of claim 1 , wherein the indicator protein is a luciferase.5. The recombinant bacteriophage of claim 1 , further comprising an untranslated region upstream of the codon-optimized indicator gene claim 1 , wherein the untranslated region includes a bacteriophage late gene promoter and a ribosomal entry site.6. A cocktail composition comprising at least two different types of recombinant bacteriophages claim 1 , wherein at least one of the recombinant bacteriophages comprises an indicator gene according to .7. A method of preparing a recombinant indicator bacteriophage comprising:selecting a wild-type bacteriophage that specifically infects a target pathogenic bacterium;preparing a homologous recombination plasmid/vector comprising an indicator gene;transforming the homologous recombination plasmid/vector into target pathogenic bacteria;infecting the transformed target pathogenic bacteria with the selected wild-type bacteriophage, thereby allowing homologous recombination to occur between the plasmid/vector and the bacteriophage genome; andisolating a particular clone of recombinant ...

Подробнее
Номер записи: 77
24-03-2022 дата публикации

OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF

Номер: US20220088097A1
Автор: Charles Stephen A., Chumakov Peter M., Chumakov Stepan P., Komar Anton A., Lipatova Anastasia V., Tararova Natalia D.
Принадлежит:

Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors. 1. A method of generating a synthetic targeted virus for a cancer cell from a reference virus for a normal cell , comprising:for each codon in a given position in the reference virus that codes for a given amino acid, identifying a codon frequency for each codon that codes for the given amino acid in the cancer cell;selecting a codon for the given amino acid in the cancer cell that best corresponds to the codon in the reference virus;using the selected codon for the given amino acid in the cancer cell in a location in the synthetic targeted virus that matches the given position in the reference virus.2. The method of claim 1 , wherein the reference virus is an oncolytic virus; orwherein the synthetic targeted virus has less than 80% identity with the reference virus.3. The method of claim 1 , wherein the codon for the given amino acid in the cancer cell that best corresponds to the codon in the reference virus is selected by (a) minimizing a difference in codon frequencies between codon pairs in the synthetic target virus and codon pairs in the reference virus; and (b) minimizing wobble in the selected codon.4. The synthetic targeted virus produced according to the method of .5. A method of generating an optimized oncolytic virus claim 1 , comprising:(i) culturing a first oncolytic virus on a first cell culture in the presence of a synthetic ribonucleoside or ribonucleotide analog to create mutagenized viruses; and(ii) culturing the mutagenized viruses on a second cell culture using serial dilution to identify the optimized oncolytic virus.6. The method of claim 5 , wherein ...

Подробнее
Номер записи: 78
24-03-2022 дата публикации

OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF

Номер: US20220088098A1
Автор: Charles Stephen A., Chumakov Peter M., Chumakov Stepan P., Komar Anton A., Lipatova Anastasia V., Tararova Natalia D.
Принадлежит:

Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors. 1. A method of treating a tumor in a dog or cat , comprising:administering to the dog or cat a first composition containing an effective amount of at least a first oncolytic virus for a first time period.2. The method of claim 1 , wherein the tumor is a mastocytoma claim 1 , an osteosarcoma claim 1 , or a mammary carcinoma.3. The method of claim 1 , wherein the first oncolytic virus is a human enterovirus; a reovirus; a paramyxovirus; a rhabdovirus; a togavirus; a Herpes virus; a parvovirus; an adenovirus; a poxvirus; or a hybrid virus.4. The method of claim 1 , wherein the first oncolytic virus is STRS1 claim 1 , STRNH1 claim 1 , STRCDV1 claim 1 , STRR1 claim 1 , STRR2 claim 1 , or STRR3.5. The method of claim 1 , wherein the first oncolytic virus is STRS1.6. The method of claim 1 , wherein the first composition comprises a plurality of oncolytic viruses.7. The method of claim 6 , wherein the plurality of oncolytic viruses includes STRS1 claim 6 , STRR1 claim 6 , and STRNH1.8. The method of claim 1 , wherein the first composition is administered multiple times during the first time period.9. The method of claim 1 , wherein the first composition is administered orally claim 1 , nasally claim 1 , intravenously claim 1 , intra-arterially claim 1 , intradermally claim 1 , subcutaneously claim 1 , intramuscularly claim 1 , intraperitoneally claim 1 , intrapleurally claim 1 , intravaginally claim 1 , intraurethrally claim 1 , intratumorally claim 1 , intracranially claim 1 , intraspinally claim 1 , or by means of a cellular carrier infected with the first oncolytic virus in ...

Подробнее
Номер записи: 79
17-03-2016 дата публикации

NOVEL KOREAN-TYPE PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS

Номер: US20160076005A1
Автор: Han Beom Ku, Kim Hyun Il, Shin Seong Ho
Принадлежит:

The present invention relates to a Korean-type porcine reproductive and respiratory syndrome virus (PRRSV) and a vaccine composition using the same, and a method for preventing porcine reproductive and respiratory syndrome. Korean-type porcine reproductive and respiratory syndrome virus with accession number KCTC 12096BP according to the present invention is Korean-type porcine reproductive and respiratory syndrome virus distinguished from European strains and North American strains, and a vaccine composition specific to Korean-type porcine reproductive and respiratory syndrome virus is produced, thereby preventing a Korean-type porcine reproductive and respiratory syndrome virus or specifically diagnosing the infection with Korean-type porcine reproductive and respiratory syndrome virus. 1. A Korean-type porcine reproductive and respiratory syndrome virus (PRRSV) (accession number KCTC 12096BP).2. A vaccine composition comprising a Korean-type porcine reproductive and respiratory syndrome virus (accession number KCTC 12096BP) as an effective ingredient.3. The vaccine composition according to claim 2 , wherein the virus is obtained by culturing the virus for 3 to 120 passages.4. The vaccine composition according to claim 2 , wherein the vaccine composition further comprises adjuvants claim 2 , excipients or carriers.5. The vaccine composition according to claim 2 , wherein the vaccine composition further comprises a protective agent.6. The vaccine composition according to claim 5 , wherein the protective agent is trehalose.7. A method for preventing porcine reproductive and respiratory syndrome claim 5 , comprising administering the virus vaccine composition according to any one of to to pigs.8. The method according to claim 7 , wherein the vaccine composition is inoculated intramuscularly or intranasally.9. The method according to claim 7 , wherein the vaccine composition comprises 2×10to 2×10PFU/ml of a Korean-type porcine reproductive and respiratory syndrome ...

Подробнее
Номер записи: 80
07-03-2019 дата публикации

Polyomavirus neutralizing antibodies

Номер: US20190071488A1
Автор: Adam Lloyd Feire, Danqing WU, Elisabetta TRAGGIAI, Fangmin Xu, Johanna ABEND, Lichun Wang, Mark Knapp, Qilong WU, Steven Kovacs, Yongqiang Wang, Zorica DRAGIC
Принадлежит: NOVARTIS AG

The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Подробнее
Номер записи: 81
07-03-2019 дата публикации

NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE

Номер: US20190071489A1
Автор: Corti Davide, Graham Barney, Lanzavecchia Antonio, Ledgerwood Julie, Malangu Sabue, Muyembe-Tamfun Jean-Jacques, Stanley Daphne, Sullivan Nancy, Trefry John
Принадлежит:

Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject. 1. An isolated monoclonal antibody , comprising:{'sub': H', 'H', 'H, 'a heavy chain variable region (V) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 of the Vset forth as SEQ ID NO: 5 (EVB166 V); and'}{'sub': L', 'L', 'L, 'a light chain variable region (V) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the Vset forth as SEQ ID NO: 6 (EVB166 V),'}wherein the monoclonal antibody or antigen binding fragment specifically binds to Ebola virus glycoprotein (GP).2. The antibody of claim 1 , wherein:the HCDR1, the HCDR2, and the HCDR3 comprise amino acids 26-33, 51-58, and 97-112 of SEQ ID NO: 5, respectively; andthe LCDR1, the LCDR2, and the LCDR3 comprise amino acids 27-33, 51-53, and 90-98 of SEQ ID NO: 6, respectively.3. The antibody of claim 1 , wherein:{'sub': 'H', 'the Vcomprises an amino acid sequence at least 80% identical to the sequence set forth as SEQ ID NO: 5;'}{'sub': 'L', 'the Vcomprises an amino acid sequence at least 80% identical to the sequence set forth as SEQ ID NO: 6; or'}{'sub': H', 'L, 'the Vcomprises an amino acid sequence at least 80% identical to the sequence set forth as SEQ ID NO: 5 and the Vcomprises an amino acid sequence at least 80% identical to the sequence set forth as SEQ ID NO: 6.'}4. The antibody of claim 1 , wherein:{'sub': 'H', 'the Vcomprises the amino acid sequence set forth as SEQ ID NO: 5;'}{'sub': 'L', 'the Vcomprises the amino acid sequence set forth as SEQ ID NO: 6; or'}{'sub': H', 'L, ' ...

Подробнее
Номер записи: 82
24-03-2022 дата публикации

EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF

Номер: US20220089694A1
Автор: DEKOSKY Brandon, Leigh Kendra Elizabeth, Misasi John, Sullivan Nancy J.
Принадлежит: The U.S.A., as represented by the Secretary, Department of Health and Human Services

Human monoclonal antibodies that specifically bind Ebola virus glycoprotein with nanomolar affinity are described. The monoclonal antibodies were isolated by bulk sorting of plasmablasts from a human Ebola virus vaccinee and pairing of the immunoglobulin heavy and light chain genes using emulsion PCR. The paired immunoglobulin genes were expressed using Fab yeast display to screen and characterize the antibodies. The Ebola virus-specific monoclonal antibodies can be used, for example, to diagnose and treat Ebola virus infection or Ebola virus disease in a subject. 1. A monoclonal antibody that specifically binds to Ebola virus (EBOV) glycoprotein (GP) , comprising a variable heavy (VH) domain and a variable light (VL) domain , wherein:(i) the VH domain comprises the VH complementarity determining region (HCDR)1, HCDR2, and HCDR3 sequences of SEQ ID NO: 2 and the VL domain comprises the VL complementarity determining region (LCDR)1, LCDR2, and LCDR3 sequences of SEQ ID NO: 4;(ii) the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 6 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 8;(iii) the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 10 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 12;(iv) the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 14 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 16;(v) the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 18 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 20;(vi) the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 22 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 24;(vii) the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 26 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 28; or(viii) the VH ...

Подробнее
Номер записи: 83
05-03-2020 дата публикации

ANIMAL MODEL OF A MOOD DISORDER AND SCREENING METHOD

Номер: US20200071363A1
Автор: KOBAYASHI Nobuyuki, KONDO Kazuhiro
Принадлежит:

Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder. 1. An animal model of a mood disorder comprising:an animal; (a) a nucleic acid encoding a protein having the amino acid sequence shown in SEQ ID NO: 1; or', '(b) a nucleic acid comprising an open reading frame region having the nucleotide sequence shown in SEQ ID NO: 2., 'wherein the animal is produced by transfer of a nucleic acid, wherein the nucleic acid selected from2. The animal model of the mood disorder according to claim 1 , wherein the animal is a mammal.3. The animal model of the mood disorder according to claim 1 , wherein the animal is a mouse.4. The animal model of the mood disorder according to claim 1 , wherein the nucleic acid is transferred into glial cells in the central nervous system.5. A screening method for performing screening for a candidate substance for a psychotropic agent claim 1 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(i) administering to the animal according to , a subject substance;'}(ii) determining whether or not the mental disorder of the animal model is cured or improved; and(iii) determining that the subject substance is a candidate substance for a psychotropic agent when the metal disorder of the animal model is determined to be cured or improved.6. The screening method for performing screening for the candidate substance for the psychotropic agent according to claim 5 , wherein in step (ii) the animal is subjected to a tail ...

Подробнее
Номер записи: 84
05-03-2020 дата публикации

HUMAN ORTHOPOXVIRUS ANTIBODIES AND METHODS OF USE THEREFOR

Номер: US20200071389A1
Автор: CROWE, GILCHUK Iuliia, JR. James E.
Принадлежит: VANDERBILT UNIVERSITY

The present disclosure is directed to antibodies binding to and neutralizing Poxvirus and methods for use thereof. 1. A method of detecting an orthopoxvirus infection in a subject comprising:(a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and(b) detecting orthopoxvirus in said sample by binding of said antibody or antibody fragment to a orthopoxvirus antigen in said sample.212-. (canceled)13. A method of treating a subject infected with orthopoxvirus , or reducing the likelihood of infection of a subject at risk of contracting orthopoxvirus , comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4 , respectively.14. The method of claim 13 , the antibody or antibody fragment is encoded by clone-paired light and heavy chain variable sequences as set forth in Table 1.15. The method of claim 13 , the antibody or antibody fragment is encoded by clone-paired light and heavy chain variable sequences having 95% identify to as set forth in Table 1.16. The method of claim 13 , wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having 70% claim 13 , 80% claim 13 , or 90% identity to clone-paired sequences from Table 1.17. The method of claim 13 , wherein said antibody or antibody fragment comprises light and heavy chain variable sequences according to clone-paired sequences from Table 2.18. The method of claim 13 , wherein said antibody or antibody fragment comprises light and heavy chain variable sequences having 70% claim 13 , 80% or 90% identity to clone-paired sequences from Table 2.19. The method of claim 13 , encoded by light and heavy chain variable sequences having 95% identity to clone-paired sequences from Table 2.20. The method of claim 13 , wherein the antibody fragment is a recombinant ScFv (single chain ...

Подробнее
Номер записи: 85
05-03-2020 дата публикации

Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases

Номер: US20200071390A1
Автор: Benoit COMBALUZIER, Ivan JELCIC, Jan Grimm, Roland Martin
Принадлежит: Neurimmune Holding AG, Universitaet Zuerich

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

Подробнее
Номер записи: 86
16-03-2017 дата публикации

RAPID TEST FOR THE QUALITATIVE AND/OR QUANTITATIVE ANALYSIS OF ANTIBODIES AGAINST HUMAN PAPILLOMA VIRUSES (HPV) PRESENT IN BODY FLUID, AND DEVICE FOR CARRYING OUT THE RAPID TEST

Номер: US20170074879A1
Автор: Hilfrich Ralf
Принадлежит:

A rapid test for a qualitative and/or quantitative assay of antibodies present in body fluid against human papilloma viruses (HPV) includes mixing a specimen of body fluid with a reagent which essentially comprises a predetermined quantity of physiologically acting liquid and a predetermined quantity of at least one HPV-specific antigen. The mixture is fed to an analysis which utilizes a change that is at least one of measurable or perceivable by a user. 115-. (canceled)16. A rapid test for at least one of a qualitative or quantitative assay of antibodies present in body fluid against human papilloma viruses (HPV) , the test comprising:{'b': '14', '(a) mixing a specimen of body fluid with a reagent () which essentially comprises a predetermined quantity of physiologically acting liquid and a predetermined quantity of at least one HPV-specific antigen to form a mixture,'}wherein the antigen is aggregated and reactive to antibodies present in the body fluid that are specific against HPV16L1 protein (HPV16L1-specific antibodies), and wherein the liquid acts on the antigen to maintain reactivity of the antigen with respect to the antibodies,(b) feeding the mixture to an analysis which utilizes a change that is at least one of measurable or perceivable by a user.17. The rapid test according to claim 16 , wherein a predetermined quantity of the mixture is fed to the analysis.18. The rapid test according to claim 16 , wherein the quantity of the at least one HPV-specific antigen is determined by a predetermined detection limit for the quantity to be determined of the at least one HPV antibody present in the fluid specimen.19. The rapid test according to claim 16 , wherein at least one type of antibodies present in the specimen against HPV is determined qualitatively by the choice of the at least one HPV-specific antigen employed.20. The rapid test according to claim 16 , wherein in the event of an absence of HPV antibodies in the specimen or a quantity of HPV antibodies in ...

Подробнее
Номер записи: 87
16-03-2017 дата публикации

METHOD FOR DETECTING CARCINOGENESIS IN THE UTERINE CERVIX

Номер: US20170074881A1
Автор: DI BENEDETTO Giuseppe, MACCALLINI Vincenzo
Принадлежит:

The invention concerns some methods for diagnosing cancer of the uterine cervix (or extra-uterine) which integrate or surrogate the field of action of cytology with that of molecular biology, and provide a system for diagnosis, prognosis and management of HPV-induced cervical lesions (or extra-uterine) which exploit, in particular, the analytical methods of Western Blot and Sandwich ELISA in order to detect those cases where the transformation towards a neoplastic lesion has become irreversible. The methods consist in detecting, in samples of cells taken from the squamous-columnar junction of the uterine cervix of a patient under examination, the proteins encoded by viral oncogenes E6 and E7 and those encoded by the tumor suppressor genes of the host cell p53 and pRB, and in detecting by Western Blot and/or by Sandwich ELISA the possible interaction between proteins E6 and p53, and between proteins E7 and pRb, as an index of irreversible transformation towards a neoplastic lesion. 1. A method for detecting a neoplastic cell transformation induced by human Papillomavirus (HPV) in women undergoing a screening for uterine cervix carcinoma , comprising detecting , in samples of cells taken from the squamous-columnar junction of the cervix epithelium of a patient being examined , the presence of a protein complex E6/p53 made by the protein E6 with the protein p53 and/or a protein complex E7/pRB made by the protein E7 with the protein pRB , wherein the detection of said two protein complexes shows that in the patient under examination the carcinogenesis has become irreversible , said detection being performed by the combined use of antibodies anti-protein E6 and antibodies anti-protein E7.3. A method according claim 2 , wherein in said step e) said proteins are also incubated with the following anti-bodies:primary monoclonal antibody anti-protein p53;primary monoclonal antibody anti-protein pRb;the further steps being similar to those carried out for the case of ...

Подробнее
Номер записи: 88
05-03-2020 дата публикации

MATERIALS AND METHODS FOR SUBJECTS AT RISK FOR VIRAL REACTIVATION

Номер: US20200072848A1
Автор: Camargo Jose, Kimble Erik, KOMANDURI Krishna, Wieder Eric
Принадлежит:

Described herein are materials and methods for stratifying risk for reactivation of a latent viral infection, such as CMV infection. The methods are particularly useful for immune compromised subjects. Also described herein are interventions, including therapeutic, prophylactic, and monitoring interventions, for subjects determined to be at elevated risk. 1. A method comprising:identifying or quantifying a risk for reactivation of a latent virus in an immune-compromised mammalian subject from measurement of a T cell subset from a sample isolated from the subject, wherein the T cell subset is identifiable from a cytokine expression profile of cytokines interleukin-2 (IL-2), interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), and macrophage inflammatory protein 1β (MIP-1β); andidentifying an elevated or high risk for reactivation of the virus in the subject from the measurement; andadministering, to the subject identified as having the elevated or high risk of viral reactivation, a prophylaxis that comprises an antiviral chemotherapeutic agent or an antiviral cellular therapy.2. (canceled)3. The method or use according to that comprises detecting or measuring expression of IL-2 claim 1 , IFNγ claim 1 , TNFα claim 1 , and MIP-1β in individual T cells from the sample by measuring mRNA encoding the cytokines in the T cells claim 1 , or measuring cytokine proteins on or in the T cells.46-. (canceled)7. The method according to claim 3 , wherein the mammalian subject is human.8. The method according to claim 1 , wherein the subject is a transplant recipient claim 1 , and wherein the identifying or quantifying risk is performed on a sample comprising the T cells obtained from the subject 14 or more days after the transplant.9. (canceled)10. The method according to claim 8 , wherein the transplant recipient is an allogeneic organ transplant recipient claim 8 , an allogeneic tissue transplant recipient claim 8 , or an allogeneic cell transplant recipient.11. The ...

Подробнее
Номер записи: 89
18-03-2021 дата публикации

Neutralizing antibodies to ebola virus glycoprotein and their use

Номер: US20210079067A1
Автор: Alberto CAGIGI, John Misasi, Kendra LEIGH, Nancy Sullivan
Принадлежит: US Department of Health and Human Services

Antibodies and antigen binding fragments that specifically bind to ebolavirus glycoprotein and neutralize ebolavirus infection are disclosed. Nucleic acids encoding these antibodies, vectors, and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an ebolavirus infection in a subject.

Подробнее
Номер записи: 90
24-03-2016 дата публикации

Attenuated African Swine Fever Virus Strain Induces Protection Against Challenge With Homologous Virulent Parental Virus Georgia 2007 Isolate

Номер: US20160082099A1
Автор: Douglas Gladue, Guillermo R. Risatti, Lauren G. HOLINKA-PATTERSON, Manuel V. Borca, Vivian K. O'DONNELL
Принадлежит: University of Connecticut, US Department of Agriculture USDA

African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for swine breeding. Control of ASF has been hampered by the unavailability of vaccines. Recombinant viruses harboring engineered deletions of specific virulence-associated genes induce solid protection against the challenge with parental viruses. Here we report the construction of a recombinant Δ9GL virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G Δ9GL administered intramuscularly (IM) to swine at relatively high doses (10 4 HAD 50 ) retains a virulent phenotype practically indistinguishable from the parental virus. Conversely, at low IM doses (10 2 or 10 3 HAD 50 ), ASFV-G Δ9GL does not induce disease. Importantly, animals infected with 10 3 HAD 50 are protected against the presentation of clinical disease when challenge at 28 days post infection with the virulent parental strain Georgia 2007.

Подробнее
Номер записи: 91
22-03-2018 дата публикации

WHOLE EXPRESSED CELL AS ANTIGEN CARRIER, AND USE THEREOF IN PREPARING VACCINE OR DIAGNOSTIC AGENT, AND SCREENING MONOCLONAL ANTIBODIES

Номер: US20180080042A1
Автор: KO Shun-Wen
Принадлежит:

A mammalian cell co-transfect with an expression plasmid comprising T7 promoter and an open reading frame (ORF) of target antigen, and a vT7 recombinant vaccinia virus expressing T7 polymerase. The entire antigen expressing cell is used as a carrier of the target antigen for preparing a vaccine or diagnostic agent, and screening monoclonal antibodies. 1. An animal cell expression system for a target antigen , comprising an animal cell co-transfected with:(a) an expression plasmid containing T7 promoter and an open reading frame (ORF) for a target antigen protein or its fragment; and{'sub': 'FBI', '(b) a vT7 recombinant vaccinia virus (vT7) expressing T7 polymerase.'}2. The animal cell expression system of claim 1 , wherein the target antigen is a viral antigen.3. The animal cell expression system of claim 2 , wherein the viral antigen is a surface protein of an enveloped virus.4. The animal cell expression system of claim 3 , wherein the enveloped virus is new variant strain of porcine epidemic diarrhea virus (PEDV).5. The animal cell expression system of claim 3 , wherein the virus is porcine circovirus type 2 (PCV2).6. The animal cell expression system of claim 2 , wherein the viral antigen is a virus-like particle of a non-enveloped virus7. The animal cell expression system of claim 6 , wherein the viral antigen is a shelled particle of foot-and mouth disease virus (FMDV)8. The animal cell expression system of claim 1 , wherein the open reading frame (ORF) of the target antigen or its fragment is fused to the downstream of the T7 promoter.9. A method for preparing the animal cell expression system of claim 1 , comprising:(1) infecting an animal cell with a recombinant vaccinia virus carrying a T7 polymerase gene; and(2) co-transfecting the infected animal cell with an expression plasmid comprising T7 promoter and an open reading frame (ORF) of the target antigen to obtain an animal cell expressing the antigen.10. The method of claim 9 , wherein the animal cell is ...

Подробнее
Номер записи: 92
14-03-2019 дата публикации

METHOD FOR THE NORMALIZATION OF IMMUNOLOGICAL TESTS AND KITS FOR PERFORMING SUCH TESTS

Номер: US20190079091A1
Автор: BOECHER Oliver, KOCH Isabel, MCNAMARA Steven, SOUTSCHEK Erwin
Принадлежит: Mikrogen GmbH

The present invention relates to a method for the normalization of an immunological test characterized in that the presence of a comparable amount of cells is determined by a sandwich ELISA test wherein the capture antibody is at least one antibody which binds to at least one keratin selected from the group consisting of keratin 4, 5, 6, 8, 10, 13 and 18 and the detection antibody is at least one antibody which binds to said keratin. 1. A method for the normalization of an immunological test , wherein said method comprises the steps of performing a first immunological test on a cell-containing biological sample derived from a patient in which the presence of a comparable amount of cells in said sample is determined by a sandwich ELISA test , wherein the sandwich ELISA test utilizes a capture antibody and a detection antibody , further wherein the capture antibody is at least one antibody that binds to at least one keratin selected from the group consisting of keratin 4 , 5 , 6 , 8 , 10 , 13 and 18 and the detection antibody is at least one antibody that binds to said keratin , together with a second test for detecting another biomarker in said biological sample.2. The method according to claim 1 , wherein the capture and the detection antibodies bind specifically to keratins 5 claim 1 , 8 and 18.3. The method according to claim 1 , wherein capture antibody and the detection antibody are the same antibodies.4. The method according to claim 1 , wherein the capture antibody and the detection antibody are different antibodies.5. The method according to claim 1 , wherein either or both of said capture and detection antibodies are monoclonal antibodies.6. The method according to claim 1 , wherein either or both of said capture and detection antibodies are a mixture of at least two different monoclonal antibodies that bind to different epitopes.7. The method according to claim 1 , wherein either or both of said capture and detection antibodies are polyclonal antibodies.8. ...

Подробнее
Номер записи: 93
23-03-2017 дата публикации

Methods Of Propagating Rhinovirus C In Previously Unsusceptible Cell Lines

Номер: US20170082609A1
Автор: Bochkov Yury A., Gern James E., Palmenberg Ann C.
Принадлежит:

The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided. 1. A method of propagating rhinovirus C or rhinovirus C variant , the method comprising the steps of:a. obtaining a host cell comprising at least one heterologous CDHR3 receptor;andb. infecting the host cell with a sample of rhinovirus C or rhinovirus C variant;wherein the rhinovirus C propagates.2. The method of wherein the CDHR3 receptor is a CDHR3-CY variant.3. The method of wherein the host cell is a cell able to support rhinovirus C replication.4. The method of wherein the host cell is selected from the group consisting of NCI-H358 claim 3 , WI-38 claim 3 , WisL claim 3 , HEK293T claim 3 , BEAS-2B claim 3 , A549 and HeLa.5. The method of wherein the CDHR3 receptor sequence is transduced into the host cell by a viral vector.6. The method of wherein the CDHR3 receptor sequence is transfected into the host cell by lipofection.7. The method of claim 1 , wherein a viral titer of at least >10e8 PFU equivalents per 10e7 cells grown in monolayer is obtained.8. A kit comprising:a. at least one host cell able to support rhinovirus C replication, wherein the host cell comprises a heterologous CDHR3 receptor; andb. a sample of rhinovirus C or rhinovirus C variant.9. The kit of wherein the host cell is selected from the group consisting of NCI-H358 claim 8 , WI-38 claim 8 , WisL claim 8 , HEK293T claim 8 , BEAS-2B claim 8 , A549 and HeLa.10. The kit of wherein the CDHR3 receptor is a CDHR3-CY variant.11. A kit comprising:a. a nucleic acid encoding a CDHR3 receptor; andb. a sample of rhinovirus C.12. The kit of wherein the CDHR3 ...

Подробнее
Номер записи: 94
31-03-2022 дата публикации

METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING EBOLA VIRUS

Номер: US20220099675A1
Автор: Chen Xiahui, Gu Liangcai, IKBAL Md Ashif, KANG Shoukai, Wang Chao, Zhao Zhi
Принадлежит:

Provided herein are methods of detecting Ebola virus in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first or second epitopes of glycoproteins, such as secreted glycoproteins (sGPs) from the Ebola virus under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first or second epitopes of the glycoproteins from the Ebola virus in the sample to produce bound glycoproteins. The methods also include detecting the glycoproteins from the Ebola virus when aggregations of the bound glycoproteins form with one another. Related reaction mixtures, devices, kits, and systems are also provided. 1. A method of detecting Ebola virus in a sample , the method comprising:contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, wherein at least a first set of antibodies, or antigen binding portions thereof, binds to a first epitope of a glycoprotein from the Ebola virus and wherein at least a second set of antibodies, or antigen binding portions thereof, binds to a second epitope of a glycoprotein from the Ebola virus under conditions sufficient for the first and second set of antibodies, or the antigen binding portions thereof, to bind to the first or second epitopes of the glycoproteins from the Ebola virus in the sample to produce bound glycoproteins; orcontacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with a single set of antibodies, or antigen binding portions thereof, that bind to an identical epitope from different monomers of a dimerized glycoprotein from the Ebola virus under conditions sufficient for the antibodies, or ...

Подробнее
Номер записи: 95
12-03-2020 дата публикации

POTENCY TEST FOR VACCINE FORMULATIONS

Номер: US20200080981A1
Автор: ALLEN MICHELLE, BRUDERER URS PETER, GARRETT MARK, THIJSSEN MARTINUS ANTONIUS JOHANNES
Принадлежит: Intervet Inc.

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen. 1. A method for the determination of an antigen content of a first antigen in a mixture of at least a composition comprising the first antigen and a composition comprising (i) a second antigen and (ii) antibodies that are capable of binding with the first antigen , the method comprising the steps of:a) dissociating antigen-antibody complexes in the mixture, formed between the first antigen and the antibodies; andb) determining the antigen content of the first antigen by means of an immunoassay.2Mycoplasma hyopneumoniae. The method of claim 1 , wherein the first antigen is a porcine circovirus type 2 (PCV-2) antigen and the second antigen is a antigen.3. The method of claim 1 , wherein the immunoassay is an ELISA (enzyme linked immunosorbent assay).4. The method of claim 1 , wherein the mixture is a ready-to-use vaccine formulation.5. The method of claim 1 , wherein the mixture is incubated with an acid solution to dissociate the antigen-antibody complexes.6. The method of claim 5 , wherein the acid solution is a citric acid solution.7. The method of claim 5 , wherein the mixture is incubated with the acid solution for at least 8 hours.8. The method of claim 5 , wherein the mixture is incubated at a ratio (v/v) between the acid solution and the mixture of at least 25 claim 5 , preferably 25-75 claim 5 , more preferably 25-50.9. The method of claim 5 , wherein the acid solution has a pH of 1.0-3.0.10Mycoplasma hyopneumoniaeM. hyo. A method for the determination of an antigen content of a porcine circovirus type 2 (PCV-2) antigen in a mixture of at least a composition comprising the PCV- ...

Подробнее
Номер записи: 96
29-03-2018 дата публикации

OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF

Номер: US20180085411A1
Автор: Charles Stephen A., Chumakov Peter M., Chumakov Stepan P., Komar Anton A., Lipatova Anastasia V., Tararova Natalia D.
Принадлежит:

Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors. 1. A method of treating a cancer patient , comprising:administering to the patient a first composition containing an effective amount of at least a first oncolytic virus for a first time period; andadministering to the patent a second composition containing an effective amount of at least a second oncolytic virus that is different from the first oncolytic virus for a second time period.2. The method of claim 1 , wherein the second composition is administered between 24 hours to 24 weeks after the first composition is administered; orwherein the second composition is administered between one week to six weeks after the first composition is administered.3. The method of claim 1 , wherein the first composition is administered multiple times during the first time period; and wherein the second composition is administered multiple times during the second time period.4. The method of claim 1 , wherein the first and second compositions are administered orally claim 1 , nasally claim 1 , intravenously claim 1 , intra-arterially claim 1 , intradermally claim 1 , subcutaneously claim 1 , intramuscularly claim 1 , intraperitoneally claim 1 , intrapleurally claim 1 , intravaginally claim 1 , intraurethrally claim 1 , intratumorally claim 1 , intracranially claim 1 , intraspinally claim 1 , or by means of a cellular carrier infected with the first or second oncolytic virus in vitro; or{'sup': 4', '11, 'wherein the first and second oncolytic viruses are present in a dosage of about 1×10TCID50 to about 1×10TCID50.'}5. The method of claim 1 , wherein the first and second oncolytic viruses ...

Подробнее
Номер записи: 97
21-03-2019 дата публикации

COMPOSITIONS AND METHODS FOR DETECTION AND MODULATION OF T CELL MEDIATED IMMUNE RESPONSES AGAINST VIRAL VECTORS UTILIZED FOR GENE THERAPY

Номер: US20190083658A1
Автор: HIGH Katherine A., Hui Daniel J., MAUS Marcela V., Mingozzi Federico
Принадлежит: THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells. 1. A soluble T cell receptor (sTCR) which is immunospecific for a peptide sequence present in an adenovirus-associated virus (AAV) in the context of a human MHC Class 1 molecule.2. The sTCR of claim 1 , wherein said adenovirus peptide sequence is obtained from a serotype selected from the group consisting of AAV-1 claim 1 , AAV-2 claim 1 , AAV-5 claim 1 , AAV-8 and other naturally occurring serotypes.3. The sTCR of claim 1 , wherein said human MHC Class I molecule is selected from the group consisting of HLA-A1 claim 1 , HLA-A2 claim 1 , HLA-A3 claim 1 , HLA-B7 claim 1 , HLA-B8 claim 1 , HLA-B15 claim 1 , HLA-B44 and HLA-B51.4. A method for detecting the presence a T cell mediated immune response against viral capsid antigen before claim 1 , during or after administration of an adeno-associated viral vector containing a transgene claim 1 , comprising:a) obtaining a biological sample from a patient, said sample comprising T cells;b) contacting said cells with a pentamer comprising a peptide epitope of said capsid in context with an MHC Class I molecule; andc) determining whether the contact of step b) stimulates said cells relative to an untreated control cell, cells being stimulated by said contact having specificity for said peptide epitope of said viral capsid, said cells promoting T cell mediated destruction of capsid and transgene containing cells.5. The method of claim 4 , wherein said biological sample comprises cells selected from the group consisting of transgene containing cells claim 4 , PBMCs claim 4 , liver cells claim 4 , epithelial cells claim 4 , and muscle cells.6. The method of further comprising isolating mRNA from said stimulated cells claim 4 , preparing cDNA and cloning a soluble T cell receptor immunospecific for said viral capsid antigen.7. A soluble T cell receptor prepared by the method of .8. A method for ...

Подробнее
Номер записи: 98
30-03-2017 дата публикации

Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same

Номер: US20170087219A1
Автор: BUNTING STUART, Colosi Peter Cameron, Pungor Erno
Принадлежит:

The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof. 1. A pharmaceutical formulation comprising a recombinant AAV FVIII virus , a buffering agent , an isotonicity agent , a bulking agent and a surfactant.2. The pharmaceutical formulation of claim 1 , wherein the recombinant AAV FVIII virus is AAV5-FVIII-SQ.3. The pharmaceutical formulation of which is stable during storage at ≦65° C. for at least 2 weeks.4. The pharmaceutical formulation of claim 1 , which comprises sodium phosphate claim 1 , dibasic at a concentration of from about 0.1 mg/ml to about 3 mg/ml claim 1 , sodium phosphate monobasic monohydrate at a concentration of from about 0.1 mg/ml to about 3 mg/ml claim 1 , sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml claim 1 , mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml claim 1 , and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml.5. (canceled)6. (canceled)7. The pharmaceutical formulation of which comprises said AAV FVIII virus at a concentration of from about 1E12 vg/ml to about 2E14 vg/ml.8. (canceled)9. (canceled)10. A method of treating a subject suffering from hemophilia A comprising administering to said subject a therapeutically effective amount of a recombinant AAV FVIII virus.11. The method of claim 10 , wherein said recombinant AAV FVIII virus is AAV5-FVIII-SQ.12. The method of claim 10 , wherein said step of administering is by intravenous administration.13. The method of claim 10 , wherein said step of administering ...

Подробнее
Номер записи: 99
02-04-2015 дата публикации

ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHODS OF THEIR USE

Номер: US20150093742A1
Автор: Belmares Michael P., Diaz-Sarmiento Chamorro Somoza, Garman Jonathan David, Lu Peter S., Schweizer Johannes
Принадлежит:

The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. 1. A monoclonal antibody that specifically binds to a sub-sequence of a common sequence of an oncogenic early gene protein from at least two oncogenic HPV strains , wherein the common sequence is an amino acid sequence motif that is generally conserved between the at least two oncogenic HPV strains.2. The monoclonal antibody of claim 1 , wherein the antibody specifically binds to an E6 peptide having SEQ ID NO: 7 claim 1 , 8 claim 1 , or 60.3. The monoclonal antibody of claim 1 , wherein the antibody specifically binds to an E6 peptide having SEQ ID NO: 9 claim 1 , 10 claim 1 , or 61.4. The monoclonal antibody of claim 1 , wherein the antibody specifically binds to an E6 peptide having SEQ ID NO: 11 claim 1 , 12 claim 1 , or 62.5. The monoclonal antibody of claim 1 , wherein the antibody specifically binds to an HPV E6 peptide having SEQ ID NO: 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 57 claim 1 , 58 claim 1 , or 59.6. The monoclonal antibody of claim 1 , wherein the antibody is cross-reactive with at least three human papilloma virus E6 proteins.7. The monoclonal antibody of claim 1 , wherein the antibody is cross-reactive with at least four human papilloma virus E6 proteins.8. The monoclonal antibody of claim 1 , wherein the antibody has a binding affinity of less than 10M.9. The monoclonal antibody of claim 1 , wherein the ...

Подробнее
Номер записи: 100